

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072548 A2

(51) International Patent Classification⁷: C07D 209/42,
A61K 31/404, A61P 43/00, C07D 401/12

(21) International Application Number: PCT/US02/07168

(22) International Filing Date: 8 March 2002 (08.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/274,900 9 March 2001 (09.03.2001) US
60/343,259 21 December 2001 (21.12.2001) US

(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL,
INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ
08869-0602 (US).

(72) Inventors: CARRUTHERS, Nicholas, I.; 14370 Silver
Heights Road, Poway, CA 92064 (US). CHAI, Wenying;
9519 Compass Point Drive South, San Diego, CA 92126
(US). DVORAK, Curt, A.; 7657 Angelino Road, San
Diego, CA 92126 (US). EDWARDS, James, P.; 8723
Hesby Court, San Diego, CA 92129 (US). GRICE,
Cheryl, A.; 3449 Camino Corte, Carlsbad, CA 92009
(US). JABLONOWSKI, Jill, A.; 13651 Freeport Road,
San Diego, CA 92129 (US). KARLSSON, Lars; 336
Fern Glen, La Jolla, CA 92037 (US). KHATUYA, Hari-
pada; 13624 Via Cima Bella, San Diego, CA 92129
(US). KREISBERG, Jennifer, D.; 12825 Caminito del
Canto, Del Mar, CA 92014 (US). KWOK, Annette,
K.; 9975 Paseo Montril, San Diego, CA 92129 (US).
LOVENBERG, Timothy, W.; 13252 Courtland Terrace,
San Diego, CA 92130 (US). LY, Kiev, S.; 10620 Dabney
Drive, #172, San Diego, CA 92126 (US). PIO, Barbara;

3898 Ashford Street, San Diego, CA 92111 (US). SHAH,
Chandravadan, R.; 14213 Dalhousie Road, San Diego,
CA 92129 (US). SUN, Siquan; 13919 Amber Sky Lane,
San Diego, CA 92129 (US). THURMOND, Robin, L.;
4654 Constance Drive, San Diego, CA 92115 (US). WEI,
Jianmei; 12516 Senda Panacea, San Diego, CA 92129
(US). XIAO, Wei; 4043 Carmel Springs Way, San Diego,
CA 92130 (US).

(74) Agent: SHEN, Evelyn, D.; Johnson & Johnson, One John-
son & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/072548 A2

(54) Title: HETEROCYCLIC COMPOUNDS

(57) Abstract: Heterocyclic compounds and methods of making them and using them.

HETEROCYCLIC COMPOUNDS

Field of the Invention

5

The invention relates to novel, pharmaceutically-active fused heterocyclic compounds and methods of using them to treat or prevent disorders and conditions mediated by the histamine H₄ receptor.

10

Background

Histamine was first identified as a hormone (Barger et al., *J. Physiology* 41:19-59, 1910) and has since been demonstrated to play a major role in a variety of physiological processes, including the inflammatory "triple response" via H₁ receptors (Ash et al., *Br. J. Pharmacology* 27:427-439, 1966), gastric acid secretion via H₂ receptors (Black et al., *Nature* 236:385-390, 1972), and neurotransmitter release in the central nervous system via H₃ receptors (Arrang et al., *Nature* 302: 832-837, 1983) (for review see Hill et al., *Pharmacol. Rev.* 49: 253-278, 1997). All three histamine receptor subtypes have been demonstrated to be members of the superfamily of G-protein coupled receptors (Gantz et al., *Proc. Natl. Acad. Sci. U. S. A.* 88:429-433, 1991; Lovenberg et al., *Mol. Pharmacol.* 55:1101-1107, 1999; Yamashita et al., *Proc. Natl. Acad. Sci. U. S. A.* 88:11515-11519, 1991). There are, however, additional functions of histamine that have been reported, for which no receptor has been identified. For example, in 1994, Raible et al. demonstrated that histamine and R- α -methylhistamine could activate calcium mobilization in human eosinophils (Raible et al., *Am. J. Respir. Crit. Care Med.* 149:1506-1511, 1994). These responses were blocked by the H₃-receptor antagonist thioperamide. However, R- α -methylhistamine was significantly less potent than histamine which was not consistent with the involvement of known H₃ receptor subtypes. Therefore, Raible et al. hypothesized the existence of a novel histamine receptor on eosinophils that was non-H₁, -H₂, or -H₃. Most recently several

groups (Oda et al., *J. Biol. Chem.* **275**(47):36781-36786, 2000; Liu et al., *Mol. Pharmacol.* **59**:420-426, 2001; Nguyen et al., *Mol. Pharmacol.* **59**:427-433, 2001; Zhu et al., *Mol. Pharmacol.* **59**(3):434-441, 2001; Morse et al., *J. Pharmacol. Exp. Ther.* **296**(3):1058-1066, 2001) have identified and 5 characterized a fourth histamine receptor subtype, the H₄ receptor. This receptor is a 390 amino-acid, seven-transmembrane G protein coupled receptor with approximately 40% homology to the histamine H₃ receptor. In contrast to the H₃ receptor, which is primarily located in the brain, the H₄ receptor is expressed at greater levels in neutrophils and mast cells, among 10 other cells, as reported by Morse et al. (see above).

Events that elicit the inflammatory response include physical stimulation (including trauma), chemical stimulation, infection, and invasion by a foreign body. The inflammatory response is characterized by pain, increased temperature, redness, swelling, reduced function, or a combination of these.

15 Many conditions, such as allergies, asthma, chronic obstructed pulmonary disease (COPD), atherosclerosis, and autoimmune diseases, including rheumatoid arthritis and lupus, are characterized by excessive or prolonged inflammation. Inhibition of leukocyte recruitment can provide significant therapeutic value. Inflammatory diseases or inflammation-mediated diseases 20 or conditions include, but are not limited to, acute inflammation, allergic inflammation, and chronic inflammation.

Mast cell de-granulation (exocytosis) leads to an inflammatory response that may be initially characterized by a histamine-modulated wheal and flare reaction. A wide variety of immunological (e.g., allergens or antibodies) and 25 non-immunological (e.g., chemical) stimuli may cause the activation, recruitment, and de-granulation of mast cells. Mast cell activation initiates allergic (H₁) inflammatory responses, which in turn cause the recruitment of other effector cells that further contribute to the inflammatory response. The histamine H₂ receptors modulate gastric acid secretion, and the histamine H₃ receptors affect neurotransmitter release in the central nervous system. 30


Examples of textbooks on the subject of inflammation include J. I. Gallin and R. Snyderman, Inflammation: Basic Principles and Clinical Correlates, 3rd Edition, (Lippincott Williams & Wilkins, Philadelphia, 1999); V. Stvrtinova, J.

Jakubovsky and I. Hulin, "Inflammation and Fever", Pathophysiology Principles of Diseases (Textbook for Medical Students, Academic Press, 1995); Cecil et al., Textbook Of Medicine, 18th Edition (W.B. Saunders Company, 1988); and Steadmans Medical Dictionary.

5 A summary of the present invention follows.

Summary of the Invention

The invention features a compound of formula (I) wherein:



Wherein R_1 is R_a , R_aR_b , R_a-O-R_b , or $(R_c)(R_d)N-R_b$, where R_a is H, cyano, $-(C=O)N(R_c)(R_d)$, $-C(=NH)(NH_2)$, C_{1-10} alkyl, C_{3-8} alkenyl, C_{3-8} cycloalkyl, C_{2-6} heterocyclic radical, or phenyl; where R_b is C_{1-8} alkylene, C_{2-8} alkenylene, C_{3-8} cycloalkylene, bivalent C_{3-8} heterocyclic radical, or phenylene; and R_c and R_d are each independently H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{3-8} cycloalkyl, or phenyl; R_2 is H, methyl, ethyl, NR_pR_q , $-(CO)NR_pR_q$, $-(CO)OR_r$, $-CH_2NR_pR_q$, or CH_2OR_r ; where R_p , R_q , and R_r are independently selected from C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl; $(C_{3-8}$ cycloalkyl) $(C_{1-2}$ alkylene), benzyl or phenethyl; or R_p and R_q taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, and N; R_3 is H, methyl, ethyl, NR_sR_t , $-(CO)NR_sR_t$, $-(CO)OR_u$, $-CH_2NR_sR_t$, or CH_2OR_u ; where R_s , R_t , and R_u are independently selected from C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl; $(C_{3-8}$ cycloalkyl) $(C_{1-2}$ alkylene), benzyl or phenethyl; or R_s and R_t taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, and N; R_5 is methyl, ethyl, or H; R_6 is methyl, ethyl, or H; R_7 is methyl, ethyl, or H;


X_4 is NR_1 or S;
 X_1 is CR_3 ;
 R_3 is F, Cl, Br, CHO, R_f , RR_g , R_fO-R_g , or $(R_h)(R_i)N-R_g$, where R_f is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, C₂₋₅ heterocyclic radical, or phenyl;
5 where R_g is C₁₋₆ alkylene, C₂₋₆ alkenylene, C₃₋₆ cycloalkylene, bivalent C₃₋₆ heterocyclic radical, or phenylene; and R_h and R_i are each independently H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, or phenyl;
 X_2 is NR_e or O, provided that X_2 is NR_e where X_1 is N; R_e is H or C₁₋₆ alkyl;
10 X_3 is N;
 Z is =O or =S;
each of R_4 and R_6 is independently H, F, Cl, Br, I, COOH, OH, nitro, amino, cyano, C₁₋₄ alkoxy, or C₁₋₄ alkyl;
 R_5 is H, F, Cl, Br, I, $(C=O)R_j$, OH, nitro, NR_jR_k , cyano, phenyl, $-OCH_2-Ph$,
15 C₁₋₄ alkoxy, or C₁₋₄ alkyl;
 R_7 is H, F, Cl, Br, I, $(C=O)R_m$, OH, nitro, NR_lR_m , cyano, phenyl, $-OCH_2-$ Ph C₁₋₄ alkoxy, or C₁₋₄ alkyl;
wherein each of R_j , R_k , R_l , and R_m is independently selected from H, C₁₋₆ alkyl, hydroxy, phenyl, benzyl, phenethyl, and C₁₋₆ alkoxy;
20 each of the above hydrocarbyl (including alkyl, alkoxy, phenyl, benzyl, cycloalkyl, and so on) or heterocyclic groups being independently and optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, halo, hydroxy, amino, and C₁₋₃ alkoxy;
wherein n is 0, 1, or 2; where n is 2, the moiety $-(CHR_5)_n=2-$ is $-(CHR_5-$
25 $CHR_7)-$ where CHR_5 is between CHR_6 and CHR_7 ;
provided at least one of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , and R_7 is other than H when Z is O;
and provided, where Z is O, n =1, and each of R_4 , R_5 , R_6 , R_7 , R_2 , R_3 , R_5 , and R_6 is H, (or at least 7, 8, or 9 of these 10 limitations apply) then (a)
30 where X_2 is NH, then R_1 is (i) not methyl, pyridyl, phenyl, or benzyl, or (ii) is selected from the disclosed possibilities, but not C₁₋₂ alkyl and not a six-membered aryl or six-membered nitrogen-containing heteroaryl, or phenyl(C₁₋₂ alkylene) (alternatively, provided, where Z is O, n =1, and X_2 is NH, then at

least two (or three) of R_4 , R_5 , R_6 , R_7 , R_2 , R_3 , R_5 , and R_6 is other than H); and
 (b) where X_2 is O, then R_1 is not methyl;

and provided, where Z is O, X_2 is NH, $n = 1$, R_1 is methyl, each of R_4 , R_6 , R_7 , R_2 , R_3 , R_5 , and R_6 is H (or at least 7, 8, 9, or 10 of these 11 limitations
 5 apply), then R_5 is (i) not methoxy, (ii) not methoxy, or ethoxy, (iii) not C_{1-4} alkoxy, or (iv) not methoxy or hydroxy;

or a pharmaceutically acceptable salt, ester, or amide thereof.

According to one aspect of the invention, the invention features compounds of the following formula (Ib):



10

(Ib)

Wherein R_1 is R_a , R_aR_b , R_a-O-R_b , or $(R_c)(R_d)N-R_b$, where R_a is H, C_{1-10} alkyl, C_{3-8} alkenyl, C_{3-8} cycloalkyl, C_{2-5} heterocyclic radical, or phenyl; where R_b is
 15 C_{1-8} alkylene, C_{3-8} alkenylene, C_{3-8} cycloalkylene, bivalent C_{3-8} heterocyclic radical, or phenylene; and R_c and R_d are each independently H, C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-8} cycloalkyl, or phenyl;

R_2 is ortho (like R_2 in formula (I)) or meta (like R_3 in formula (I)), and is methyl or H;

20 X_1 is CR_3 ;

R_3 is F, Cl, Br, R_f , R_fR_g , R_f-O-R_g , or $(R_h)(R_i)N-R_g$, where R_f is H, C_{1-8} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{2-5} heterocyclic radical, or phenyl; where R_g is C_{1-8} alkylene, C_{2-6} alkenylene, C_{3-6} cycloalkylene, bivalent C_{3-8} heterocyclic radical, or phenylene; and R_h and R_i are each independently H, C_{1-8} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, or phenyl;

X_2 is NR_e or O, provided that X_2 is NR_e when X_1 is N; R_e is H or C₁₋₆ alkyl;

X_3 is N;

Z is =O or =S;

5 each of R_4 and R_6 is independently H, F, Cl, Br, I, COOH, OH, nitro, amino, cyano, C₁₋₄ alkoxy, or C₁₋₄ alkyl;

R_5 is H, F, Cl, Br, I, (C=O)R_j, OH, nitro, NR_jR_k, cyano, -OCH₂-Ph, C₁₋₄ alkoxy, or C₁₋₄ alkyl;

10 R_7 is H, F, Cl, Br, I, (C=O)R_m, OH, nitro, NR_jR_m, cyano, C₁₋₄ alkoxy, or C₁₋₄ alkyl;

wherein each of R_j , R_k , R_l , and R_m is independently selected from H, C₁₋₆ alkyl, hydroxy, and C₁₋₆ alkoxy; and

each of the above hydrocarbyl or heterocyclic groups being

15 independently and optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, halo, hydroxy, amino, and C₁₋₃ alkoxy;

provided at least one of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , and R_7 is other than H when Z is =O;

or a pharmaceutically acceptable salt, ester, or amide thereof.

20 The invention also features methods of making and using such compounds in pharmaceutical composition, packaged drugs, and in the treatment or prevention of H₄-mediated diseases and conditions, particularly those wherein it is desirable to antagonize the H₄ receptor. For example, the expression of the H₄ receptor in immune cells, including some leukocytes and

25 mast cells, establishes it as an important target for therapeutic intervention in a range of immunological and inflammatory disorders (such as allergic, chronic, or acute inflammation). Specifically H₄ receptor ligands are expected to be useful for the treatment or prevention of various mammalian disease states. Examples include: inflammatory disorders (such as those mediated by

30 leukocytes or mast cells), asthma, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, allergic disorders, autoimmune disease, lymphatic disorders, atherosclerosis, and immunodeficiency disorders.

In addition, H₄ receptor ligands may be useful as adjuvants to chemotherapy. In the above methods of treatment, the invention also includes using compounds described in formula (I) and (Ib) without the provisos such as "provided at least one of R₁, R₂, R₃, R₄, R₅, R₆, and R₇ is other than H when Z is O" above in pharmaceutical compositions for treating H₄-mediated conditions, and in methods of treatment of H₄-mediated diseases. Such a compound is, for example, Example 4.

Important synthetic intermediates of the above compounds include those wherein one or more of R₄, R₅, R₆ and R₇ is Br, I, cyano, nitro, alkoxy, or -OCH₂Ph, which can be further modified to provide a wide range of substituents.

Other features and advantages of the invention will be apparent in the following detailed description, examples, and the appended claims.

15

Detailed Description

The invention features compounds of formulae (I) and (Ib), methods of making them, and methods of using them in the preparation of pharmaceutical compositions for the treatment or prevention of H₄-mediated diseases and conditions.

20

A. Terms

The following terms are defined below, and by their usage throughout the disclosure.

"Alkyl" includes straight chain and branched hydrocarbons with at least one hydrogen removed to form a radical group. Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl, isopentyl, sec-pentyl, hexyl, heptyl, octyl, and so on. Alkyl does not include cycloalkyl.

"Alkenyl" includes straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon double bond (sp²). Alkenyls include ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), isopropenyl (or 1-methylvinyl), but-1-enyl, but-2-enyl, butadienyls, pentenyls, hexa-2,4-dienyl, and so on. Hydrocarbon radicals having a mixture of double bonds and triple

bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein. Alkenyl does not include cycloalkenyl.

"Alkynyl" include straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon triple bond (sp). Alkynyls include 5 ethynyl, propynyls, butynyls, and pentynyls. Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein. Alkynyl does not include cycloalkynyl.

"Alkoxy" includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes 10 methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on. "Aminoalkyl", "thioalkyl", and "sulfonylalkyl" are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO_2 .

"Aryl" includes phenyl, naphthyl, biphenylyl, and so on.

"Cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 15 cycloheptyl, cyclooctyl, and so on.

"Cycloalkenyl" includes cyclobutenyl, cyclobutadienyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cyclohexatrienyl (phenyl), cycloheptenyl, and so on. "Cycloalkynyl" includes the analogous rings with one or more triple bonds.

20 "Heterocyclic radicals" include aromatic and nonaromatic rings having carbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety (SO_2 , CO, CONH, COO) in the ring. Unless otherwise indicated, a heterocyclic radical may have a valence connecting it to the rest of the molecule through a carbon atom, such as 3-furyl or 2-imidazolyl, or through a heteroatom, such as 25 N-piperidyl or 1-pyrazolyl. Examples of heterocyclic radicals include thiazoyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, 30 indolinyl, and morpholinyl. For example, preferred heterocyclic radicals for R_a include morpholinyl, piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino, cycloheptylimino, and more preferably, piperidyl.

"Halo" includes fluoro, chloro, bromo, and iodo, and preferably fluoro or chloro.

"Patient" or "subject" includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of 5 observation, experiment, treatment or prevention in connection with the relevant disease or condition. Preferably, the patient is a human.

"Composition" includes a product comprising the specified ingredients in the specified amounts as well as any product that results directly or indirectly from combinations of the specified ingredients in the specified amounts.

10 Concerning the various radicals in this disclosure and in the claims, two general remarks are made. The first remark concerns valency. As with all hydrocarbon radicals (hydrocarbyl), whether saturated, unsaturated or aromatic, and whether or not cyclic, straight chain, or branched, and also similarly with all heterocyclic radicals, each radical includes substituted radicals 15 of that type and monovalent, bivalent, and multivalent radicals as indicated by the context of the claims. Hydrocarbyl includes alkoxy, in that the alkyl portion of an alkoxy group may be substituted. The context will indicate that the substituent is an alkylene or hydrocarbon radical with at least two hydrogen atoms removed (bivalent) or more hydrogen atoms removed (multivalent). An 20 example of a bivalent radical linking two parts of the molecule is R_b in formula (I), which can link $N(R_c)(R_d)$ with the ring nitrogen atom of the rest of the molecule. Another example of a bivalent moiety is an alkylene or alkenylene.

Second, radicals or structure fragments as defined herein are understood to include substituted radicals or structure fragments. Using "alkyl" 25 as an example, "alkyl" should be understood to include substituted alkyl having one or more substitutions, such as between 1 and 5, 1 and 3, or 2 and 4 substituents. The substituents may be the same (dihydroxy, dimethyl), similar (chlorofluoro), or different (chlorobenzyl- or aminomethyl-substituted).

Examples of substituted alkyl include haloalkyl (such as fluoromethyl, 30 chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, and 3-iodocyclopentyl), hydroxyalkyl, aminoalkyl, nitroalkyl, alkylalkyl, and so on. Preferred substitutions for R_a include methyl, methoxy, trifluoromethoxy, difluoromethoxy, fluoromethoxy, fluoromethyl, difluoromethyl, perfluoromethyl

(trifluoromethyl), 1-fluoroethyl, 2-fluoroethyl, ethoxy, fluoroethoxy, fluoro, chloro, and bromo, and particularly methyl, fluoromethyl, perfluoro, trifluoromethoxy, difluoromethoxy, methoxy, and fluoro.

B. Compounds

The invention features compounds of formula (I) and (Ib). Preferred compounds include those wherein: (a) X_1 is CR_3 ; (b) X_3 is N; (c) X_2 is N; (d) R_1 is H, methyl, or ethyl; (e) X_2 is N and X_1 is CR_3 ; (f) X_2 is O and X_1 is CR_3 ; (g) X_2 is N and Z is O; (h) R_7 is H or Cl; (i) R_1 is methyl or ethyl; (j) R_3 or R_2 is, or both are, H; (k) R_3 is H or Cl; (l) each of R_5 and R_7 is independently selected from H, F, Cl, and Br; (m) R_3 is Cl; (n) at least one of R_5 and R_7 is F, Cl, Br, or methyl; (o) R_5 or R_7 , or both is (are independently selected from) H, F, Cl, or Br; (p) R_3 or R_2 is methyl where R_1 is H; R_3 or R_2 is otherwise H; or (q) at least one of R_5 and R_7 is not H; or (r) combinations thereof.

Additional examples of preferred compounds or combinations of the above include those wherein:

- (s) X_3 is N; R_3 is H or Cl; R_5 is F, Cl, Br, or methyl; and R_7 is H, F, Cl, or Br;
- (t) R_3 is H or Cl; R_5 is F, Cl, Br, or methyl; and R_7 is H, F, Cl, Br, or methyl;
- (u) R_2 is methyl where R_1 is H; R_2 is otherwise H; X_1 is CR_3 ; R_3 is H, F, or Cl; X_2 is NR_e or O, provided that X_2 is NR_e where X_1 is N; R_e is H or C₁₋₃ alkyl; Z is =O or =S; each of R_4 and R_6 is independently H, OH, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, or amino; R_5 is H, F, Cl, Br, (C=O)R₁, OH, amino, cyano, C₁₋₄ alkoxy, or C₁₋₄ alkyl; R_7 is H, F, Cl, Br, (C=O)R_m, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, or amino; and
- (v) R_3 and R_2 is methyl or H; X_1 is CR_3 ; R_3 is H, F, or Cl; X_2 is NR_e or O, provided that X_2 is NR_e where X_1 is N; R_e is H or C₁₋₆ alkyl; Z is =O or =S; each of R_4 and R_6 is H; R_5 is H, F, Cl, Br, methyl, ethyl, or propyl; and R_7 is H, F, Cl, Br, or C₁₋₄ alkyl.

Examples of compounds include: (4-Methyl-piperazin-1-yl)-(5-trifluoromethyl-1H-indol-2-yl)-methanone; (7-Amino-5-methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Amino-7-methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (7-Amino-5-bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Amino-7-bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Fluoro-7-methyl-1H-indol-2-yl)-(4-methyl-

5 piperazin-1-yl)-methanone; (7-Fluoro-5-methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (6-Bromo-5-hydroxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-6-hydroxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (6-Bromo-7-hydroxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (4-Bromo-7-hydroxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (4-Bromo-7-methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone.

10 Additional examples of compounds include: (5,7-Dichloro-1H-indol-2-yl)-piperazin-1-yl-methanone; (5,7-Difluoro-1H-indol-2-yl)-piperazin-1-yl-methanone; (5,7-Difluoro-1H-indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone; (5,6-Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (4,6-Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone.

15 Further examples of compounds include: 1-(5-Chloro-1H-indole-2-carbonyl)-4-methyl-piperazine-2-carboxylic acid methyl ester; 4-(5-Chloro-1H-indole-2-carbonyl)-1-methyl-piperazine-2-carboxylic acid methyl ester; 4-(5-Chloro-1H-indole-2-carbonyl)-1-methyl-piperazine-2-carboxylic acid amide; 1-(5-Chloro-1H-indole-2-carbonyl)-4-methyl-piperazine-2-carboxylic acid amide; 4-(5-Chloro-1H-indole-2-carbonyl)-1-methyl-piperazine-2-carboxylic acid methylamide; 1-(5-Chloro-1H-indole-2-carbonyl)-4-methyl-piperazine-2-carboxylic acid methylamide; 4-(5-Chloro-1H-indole-2-carbonyl)-1-methyl-piperazine-2-carboxylic acid dimethylamide; 1-(5-Chloro-1H-indole-2-carbonyl)-4-methyl-piperazine-2-carboxylic acid dimethylamide; (5-Chloro-1H-indol-2-yl)-(3-hydroxymethyl-4-methyl-piperazin-1-yl)-methanone; (5-Chloro-1H-indol-2-yl)-(3-methoxymethyl-4-methyl-piperazin-1-yl)-methanone; (5-Chloro-1H-indol-2-yl)-(2-methoxymethyl-4-methyl-piperazin-1-yl)-methanone; (5-Chloro-1H-indol-2-yl)-(4-methyl-3-methylaminomethyl-piperazin-1-yl)-methanone; (5-Chloro-1H-indol-2-yl)-(4-methyl-2-methylaminomethyl-piperazin-1-yl)-methanone; (5-Chloro-1H-indol-2-yl)-(3-dimethylaminomethyl-4-methyl-piperazin-1-yl)-methanone; and (5-Chloro-1H-indol-2-yl)-(2-dimethylaminomethyl-4-methyl-piperazin-1-yl)-methanone.

Examples of preferred compounds include: (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Fluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5,7-Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (7-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5,7-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (3,5-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone. More preferred compounds in this group include (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5,7-Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Fluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (7-Amino-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (7-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (5,7-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone.

Further examples of preferred compounds include (6-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (1H-Indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone; (7-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-benzofuran-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanethione.


The most preferred compound is (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone.

The disclosed compounds can be prepared according to the next section.

C. Synthesis


The disclosed compounds may be made by combinatorial or traditional organic synthetic methods, as outlined below in Schemes 1-12 and Chemical Examples 1-86, or by analogous reactions.

5



Scheme 1

Compounds of formula III may be prepared from the compounds of formula II using conventional methods of amide bond formation. For example the carboxyl group of compound II may be activated as an active ester, acid chloride, anhydride, mixed anhydride, carbonic mixed anhydride or the like and treated with an amine containing group to give a compound of formula III. For example the compound of formula II may be converted to the corresponding active ester upon treatment with 1-hydroxybenzotriazole in the presence of a carbodiimide for example dicyclohexylcarbodiimide or 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride in the presence of a base such as triethylamine or N, N-diisopropylethylamine to give a compound of formula III. In a preferred embodiment the compound of formula II is treated with O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluroniumhexafluoro-phosphate, (HATU) and 1-hydroxy-7-azabenzotriazole, (HOAT) and N, N-diisopropylethylamine in a solvent, for example DMF, THF or the like, together with an amine component IV to give a compound of formula III. In an additional preferred embodiment a compound of formula II may be treated with carbonyldiimidazole (CDI) in a solvent, for example THF, DMF, dichloromethane or the like, followed by an amine component IV to give a compound of formula III.



Scheme 2

5 Compounds of formula III may be prepared according to the Fischer-Indole synthesis, which involves the condensation of a phenylhydrazine with an aldehyde or ketone to give an intermediate hydrazone. Thus a compound of formula V may be condensed with ethylpyruvate, usually in the presence of an acid catalyst, for example sulfuric acid to afford a hydrazone of formula VI.


10 Compounds of formula VI may be converted into indoles of formula VII upon treatment with a protic or Lewis acid, if required at elevated temperature, to effect cyclisation. Examples of acids include; polyphosphoric acid, para-toluenesulfonic acid, pyridine hydrochloride, zinc chloride, phosphorus trichloride, polyphosphoric acid trimethylsilyl ester and acetic acid. Compound

15 VI may also be converted to compound VII under thermal conditions by heating a compound of formula VI in a solvent, for example ethylene glycol, tetralin, or the like at elevated temperature, for example at about 150 to 250 °C. It will be recognized by one skilled in the art that cyclization of compounds of formula VI to compounds of formula VII can give rise to isomers when compounds of

formula V contain substituents. It will be further recognized that the conditions to effect cyclization may be different for different compounds of formula VI.


In a further embodiment, compounds of formula VII may be prepared by condensing an appropriately substituted 2-nitrotoluene with an oxalate di-ester 5 in the presence of a base followed by reduction of the intermediate to afford a compound of formula VII. In a preferred embodiment, a 2-nitrotoluene is condensed with ethylpyruvate in the presence of a base such as sodium methoxide, sodium butoxide, or sodium ethoxide in a solvent such as ethanol, methanol, or butanol. For example, a solution of 2-nitrotoluene in ethanol is 10 heated with ethylpyruvate in the presence of sodium ethoxide at reflux temperature. The condensation product may be converted to a compound of formula VII using a reducing agent, preferably zinc in aqueous acetic acid. Compounds of formula VII may be converted to compounds of formula II using standard methods for ester hydrolysis, for example upon treatment with 15 aqueous acid or base, if necessary at elevated temperature. In a preferred embodiment hydrolysis may be effected upon treating a compound of formula VII with a solution of lithium hydroxide in an alcoholic solvent, preferably ethanol. Compounds of formula II may be converted to compounds of formula III according to the procedures described previously.

20



Scheme 3


Compounds of formula IX may be prepared from the compounds of 25 formula VIII using conventional methods of amide bond formation as described for the preparation of compounds of formula III from compounds of formula II by condensing the appropriate carboxylic acid of formula VIII with an amine component IV.



Scheme 4

5 Compounds of formula III may also be prepared as depicted in Scheme 4. Treatment of an optionally substituted 2-nitrotoluene (formula X) with an oxalate, such as diethyl oxalate, in the presence of a base affords a 2-keto ester of formula XI. Typical bases used to effect this transformation include potassium ethoxide, sodium hydride, and lithium t-butoxide. Reduction of the 10 nitro group of a compound of formula XI to the corresponding aniline is accompanied by cyclization to the indole 2-carboxylate, a compound of formula VII. Typical reducers for this transformation include hydrogen over palladium, tin(II) chloride, and sulfur. Compounds of formula VII may be converted to compounds of formula II using standard methods for ester hydrolysis, for 15 example upon treatment with aqueous acid or base, if necessary at elevated temperature. In a preferred embodiment hydrolysis may be effected upon treating a compound of formula VII with a solution of lithium hydroxide in THF. Conversion to the target compounds III is effected as described in Scheme 2.


20 Formulae XII and XIII do not exist in this disclosure.



Scheme 5


Compounds of formula III may be also be prepared from compounds of formula II by condensing a piperazine-1-carboxylic acid tert-butyl ester of formula XIV with a compound of formula II using conventional methods of amide bond formation as described for the preparation of compounds of formula III from compounds of formula II. In a preferred embodiment a compound of formula II is treated with carbonyldiimidazole (CDI) in a solvent, for example THF, DMF, dichloromethane or the like, followed a piperazine-1-carboxylic acid tert-butyl ester of formula XIV to afford a compound of formula XV. Compound XV may be converted to a compound of formula XVI upon treatment with an acid, for example trifluoroacetic acid or hydrochloric acid in a solvent, for example dichloromethane, THF, dioxane or the like. In a preferred embodiment the acid is trifluoroacetic acid and the solvent dichloromethane. A compound of formula III may be obtained from a compound of formula XVI upon treatment with an alkylating agent in the presence of a base. Suitable alkylating agents include, alkylbromides, alkylchlorides, alkyl iodides, alkylmesylates, and alkyltosylates. This transformation is effected in the

presence of a base, for example potassium carbonate, sodium hydroxide, triethylamine and the like, in a solvent, for example ethanol, methanol, acetone, dichloromethane, DMF, THF and the like. Preferred conditions use potassium carbonate in acetone. The reaction may be carried out at elevated 5 temperature, preferably at about 50 °C.



Scheme 6


10 Compounds of formula XVIII may be prepared from compounds of formula XVII according to known methods for the functionalization of the indole nucleus at C-3. Such methods include, but are not limited to; halogenation, for example treatment with a halogen source in a solvent, for example upon treatment with bromine in acetic acid, N-chlorosuccinamide, N-
 15 bromosuccinamide, N-iodosuccinamide in dichloromethane, carbontetrachloride, chloroform or the like; formylation, for example by heating a DMF solution of a compound of formula XVII with phosphorus oxychloride (Vilsmeier-Haack conditions); aminoalkylation, for example by treating a compound of formula XVII with a mixture of an amine and a source of
 20 formaldehyde (Mannich conditions). One skilled in the art will recognize that not all reactions of indoles with electrophiles will lead to substitution at C-3 alone and that additional substitution may also take place and that mixtures of products may be obtained. It may be further recognized that the products of the substitution reactions (3-substituted indoles) may be used for further
 25 transformations.



Scheme 7

10 A compound of formula XX may be obtained from a compound of formula XIX upon treatment with 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide (also known as Lawesson's reagent) in a solvent for example ether, THF or dioxane. In a preferred embodiment the compound of formula XIX is treated with Lawesson's reagent in THF at ambient temperature to give a compound of formula XX.


10



Scheme 8

15 A compound of formula XXI may be obtained from a compound of formula XIX using conventional methods for amide bond reduction. For example using lithium aluminum hydride in THF, magnesium aluminum hydride in THF, lithium trimethoxyaluminum hydride, sodium bis(2-methoxyethoxy)-aluminum hydride, alane in THF and borane or borane-dimethyl sulfide complex in THF. A preferred method is the use of lithium aluminum hydride in a solvent, for example THF, dioxane, ether or the like at from 25 °C to the boiling point of the selected solvent. In a more preferred embodiment the reducing agent is lithium aluminum hydride in THF at reflux temperature.


20 As shown in the scheme below, compounds of formula XI may be prepared by utilizing a Phillips-type reaction that involves the condensation of an *ortho*-arylene diamine with a carboxylic acid or the like, to generate the benzimidazole core. Accordingly, a compound of formula XXII may be



Scheme 9

condensed with glycolic acid and typically with an acid catalyst, for example hydrochloric acid, to afford compounds of formula XXIII. It will be recognized by one skilled in the art that the condensation of compounds of formula XXII to compounds of formula XXIII can give rise to isomers when compounds of formula XXII contain substituents. Compounds of formula XXIII may be oxidized with a suitable oxidizing agent to give compounds of formula X.

Oxidants may include potassium permanganate, chromium trioxide, sodium hypochlorite, dimethyl sulfoxide with oxalyl chloride, manganese dioxide or any combination thereof. Compounds of formula X may be converted to compounds of formula XI according to the procedures described previously for compounds of formula II by condensing the appropriate carboxylic acid of formula X with an amine component IV.




Scheme 10 illustrates methods of making substituted proximal and distal regioisomers. Analogous methods may be used with rings of other than 6 members, such as 5- or 7- membered rings. Further modifications may be


made to change the hydroxymethyl and the methyl ester substituents using methods well known to those skilled in the art, including, but not limited to, those methods detailed in Schemes 11 and 12. Piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester can be prepared according 5 to the procedure of Bigge et al. (*Tetrahedron Lett.* 30:5193-5196, 1989). Selective deprotection of either the CBz or the BOC group can be accomplished using standard methods. For example, selective removal of the CBz group of piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester can be accomplished upon treatment with, but not limited 10 to, H₂ and Pd/C or ammonium formate and Pd/C in solvents such as ethanol or ethyl acetate or the like, to give piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester. Conversion of piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester to 4-methyl-piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester can be accomplished using standard conditions for 15 reductive amination. These include, but are not limited to, treatment with paraformaldehyde in the presence of a reducing agent such as sodium borohydride, sodium cyanoborohydride or sodium triacetoxyborohydride or the like, in a solvent such as tetrahydrofuran, methanol, ethanol, 1,2-dichloroethane, trifluoroethanol, or the like. One skilled in the art will recognize 20 that addition of acid to decrease the pH of the reaction mixture to a pH of less than about 7 may be necessary to effect reaction, wherein the acid is added as needed and is such as acetic acid, hydrochloric acid, and the like. Preferred reducing agents are sodium cyanoborohydride or sodium triacetoxyborohydride. Removal the the BOC group can be accomplished upon treatment 25 with an acid, for example trifluoroacetic acid or hydrochloric acid in a solvent, for example dichloromethane, THF, dioxane or the like to give 1-methyl-piperazine-2-carboxylic acid methyl ester. Reduction of the methyl ester can be accomplished using standard conditions including, but not limited to, treatment with reducing agents such as lithium aluminum hydride or 30 diisobutylaluminum hydride or the like, in solvents such as THF or diethyl ether or the like to afford (1-methyl-piperazin-2-yl)-methanol.

Alternatively, selective removal of the BOC group of piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester can be

accomplished upon treatment with an acid, for example trifluoroacetic acid or hydrochloric acid in a solvent, for example dichloromethane, THF, dioxane or the like to give piperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester. Conversion of piperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester to 5 4-methyl-piperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester can be accomplished using standard conditions for reductive amination. These include, but are not limited to, treatment with paraformaldehyde in the presence of a reducing agent such as sodium borohydride, sodium cyanoborohydride or sodium triacetoxyborohydride, or the like, in a solvent such as tetrahydrofuran, 10 methanol, ethanol, 1,2-dichloroethane, trifluoroethanol, or the like. One skilled in the art will recognize that addition of acid to decrease the pH of the reaction mixture to a pH of less than about 7 may be necessary to effect reaction, wherein the acid is added as needed and is such as acetic acid, hydrochloric acid, or the like. Preferred reducing agents are sodium cyanoborohydride or 15 sodium triacetoxyborohydride. Removal of the CBz group of 4-methyl-piperazine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester can be accomplished upon treatment with, but not limited to, H₂ and Pd/C or ammonium formate and Pd/C in sovents such as ethanol or ethyl acetate or the like, to give 4-methyl-piperazine-2-carboxylic acid methyl ester. Reduction of 20 the methyl ester can be accomplished using standard conditions including, but not limited, to treatment with reducing agents such as lithium aluminum hydride or diisobutylaluminum hydride or the like, in solvents such as THF or diethyl ether or the like, to afford (4-methyl-piperazin-2-yl)-methanol.



Scheme 11



Scheme 12

5

Compounds of formulas XXIV and XXVII may be prepared from compounds of formula II using conventional methods of amide bond formation, as described for the preparation of compounds of formula III from compounds of formula II, by condensing the appropriate carboxylic acid of formula II with an amine component such as those described in Scheme 10. Schemes 11 and 12

illustrate non-limiting methods for providing the substituted rings, such as the substituted piperazines shown in compounds XXVI and XXIX. For Scheme 11, hydrolysis of the ester can be accomplished using standard methods for ester hydrolysis, for example upon treatment with aqueous acid or base, if necessary

5 at elevated temperature. Compounds of formula XXVI where Y is nitrogen can be prepared using conventional methods of amide bond formation, as described for the preparation of compounds of formula III from compounds of formula II, by condensing the appropriate carboxylic acid of formula XXV with a suitable amine component. Compounds of formula XXVI where Y is oxygen

10 can be prepared using conventional methods of ester formation such as, but not limited to, conversion to the acid chloride using reagents such as oxalyl chloride, or the like, followed by treatment with an appropriate alcohol. For Scheme 12, compounds of formula XXVIII can be prepared from compounds of formula XXVII using conventional methods such as, but not limited to,

15 treatment with triphenylphosphine and carbon tetrabromide, thionyl bromide or HBr. Compounds of formula XXVIII may be treated with alcohols or amines to afford compounds of formula XXIX where Y is oxygen or nitrogen respectively, possibly in the presence of a suitable base such as, but not limited to, cesium carbonate or triethylamine.

D. Uses

According to the invention, the disclosed compounds and compositions are useful for the amelioration of symptoms associated with, the treatment of, and the prevention of, the following conditions and diseases: inflammatory disorders, asthma, atherosclerosis, psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, allergic disorders, dermatological disorders, autoimmune disease, lymphatic disorders, and immunodeficiency disorders. The disclosed compounds may also be useful as adjuvants in chemotherapy or in the treatment of itchy skin. The invention also features pharmaceutical compositions that include, without limitation, one or more of the disclosed compounds, and pharmaceutically acceptable carrier or excipient.

Aspects of the invention include (a) a pharmaceutical composition comprising a compound of formula (I) or (Ib), or one or more preferred compounds as described herein, and a pharmaceutically acceptable carrier; (b) a packaged drug comprising (1) a pharmaceutical composition comprising a compound of claim 1, 2, or 3 and a pharmaceutically acceptable carrier, and (2) instructions for the administration of said composition for the treatment or prevention of an H₄-mediated disease or condition.

The invention also provides a method for treating an H₄-mediated condition in a patient, said method comprising administering to the patient a pharmaceutically effective amount of a composition comprising a compound of formula (I) or (Ib) or other disclosed or preferred compounds. For example, the invention features a method for treating an H₄ mediated condition in a patient, said method comprising administering to the patient a pharmaceutically effective H₄-antagonizing amount of a composition comprising a compound of formula (I) or (Ib) or other disclosed or preferred compounds.

The effect of an antagonist may also be produced by an inverse agonist. Inverse agonism describes the property of a compound to actively turn off a receptor that displays constitutive activity. Constitutive activity can be identified in cells that have been forced to over-express the human H₄ receptor. Constitutive activity can be measured by examining cAMP levels or by

measuring a reporter gene sensitive to cAMP levels after a treatment with a cAMP-stimulating agent such as forskolin. Cells that over-express H₄ receptors will display lower cAMP levels after forskolin treatment than non-expressing cells. Compounds that behave as H₄ agonists will dose-dependently lower 5 forskolin-stimulated cAMP levels in H₄-expressing cells. Compounds that behave as inverse H₄ agonists will dose-dependently stimulate cAMP levels in H₄-expressing cells. Compounds that behave as H₄ antagonists will block either H₄ agonist-induced inhibition of cAMP or inverse H₄ agonist-induced increases in cAMP.

10 Further embodiments of the invention include disclosed compounds that are inhibitors of a mammalian histamine H₄ receptor function, inhibitors of inflammation or inflammatory responses *in vivo* or *in vitro*, modulators of the expression of a mammalian histamine H₄ receptor protein, inhibitors of polymorphonuclear leukocyte activation *in vivo* or *in vitro*, or combinations of 15 the above, and corresponding methods of treatment, prophylaxis, and diagnosis comprising the use of a disclosed compound.

1. Dosages

Those skilled in the art will be able to determine, according to known 20 methods, the appropriate dosage for a patient, taking into account factors such as age, weight, general health, the type of symptoms requiring treatment, and the presence of other medications. In general, an effective amount will be between 0.01 and 1000 mg/kg per day, preferably between 0.5 and 300 mg/kg body weight, and daily dosages will be between 10 and 5000 mg for an adult 25 subject of normal weight. Capsules, tablets or other formulations (such as liquids and film-coated tablets) may be of between 0.5 and 200 mg, such as 1, 3, 5, 10, 15, 25, 35, 50 mg, 60 mg, and 100 mg and can be administered according to the disclosed methods.

30 2. Formulations

Dosage unit forms include tablets, capsules, pills, powders, granules, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers adapted for subdivision into individual doses.

Dosage unit forms can also be adapted for various methods of administration, including controlled release formulations, such as subcutaneous implants.

Administration methods include oral, rectal, parenteral (intravenous, intramuscular, subcutaneous), intracisternal, intravaginal, intraperitoneal,

5 intravesical, local (drops, powders, ointments, gels or cream), and by inhalation (a buccal or nasal spray).

Parenteral formulations include pharmaceutically acceptable aqueous or nonaqueous solutions, dispersion, suspensions, emulsions, and sterile powders for the preparation thereof. Examples of carriers include water,

10 ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size. Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, 15 (f) absorption accelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propellants.

Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as a sugar or

20 sodium chloride; absorption-prolonging agents such as aluminum monostearate and gelatin; and absorption-enhancing agents.

3. Related Compounds

The invention provides the disclosed compounds and closely related, 25 pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms.

Pharmaceutically acceptable salts, esters, and amides include carboxylate salts (e.g., C₁₋₈ alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic 30 heterocyclic) amino acid addition salts, esters, and amides that are within a reasonable benefit/risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. Representative salts include hydrobromide, hydrochloride, sulfate,

bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate. These may include alkali metal and alkali earth cations such

5 as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine. See example, S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1-19, which is incorporated herein by reference. Representative pharmaceutically acceptable

10 amides of the invention include those derived from ammonia, primary C₁₋₆ alkyl amines and secondary di (C₁₋₆ alkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from ammonia, C₁₋₃ alkyl primary amines, and di

15 (C₁₋₂ alkyl)amines. Representative pharmaceutically acceptable esters of the invention include C₁₋₇ alkyl, C₅₋₇ cycloalkyl, phenyl, and phenyl(C₁₋₆)alkyl esters. Preferred esters include methyl esters.

The invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting group. Some of these masked or protected compounds are pharmaceutically acceptable; others will be useful as intermediates. Synthetic intermediates and processes disclosed herein, and minor modifications thereof, are also within the scope of the invention.

25 HYDROXYL PROTECTING GROUPS

Protection for the hydroxyl group includes methyl ethers, substituted methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl ethers.

30

Substituted Methyl Ethers

Examples of substituted methyl ethers include methoxymethyl, methylthiomethyl, *t*-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl,

benzyloxymethyl, *p*-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, guaiacolmethyl, *t*-butoxymethyl, 4-pentenylloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, 5 tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxido, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl and 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl.

10

Substituted Ethyl Ethers

Examples of substituted ethyl ethers include 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 15 (phenylselenyl)ethyl, *t*-butyl, allyl, *p*-chlorophenyl, *p*-methoxyphenyl, 2,4-dinitrophenyl, and benzyl.

Substituted Benzyl Ethers

Examples of substituted benzyl ethers include *p*-methoxybenzyl, 3,4-dimethoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-halobenzyl, 2,6-dichlorobenzyl, *p*-cyanobenzyl, *p*-phenylbenzyl, 2- and 4-picoly, 3-methyl-2-picoly N-oxido, diphenylmethyl, *p*, *p*'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α -naphthylidiphenylmethyl, *p*-methoxyphenylidiphenylmethyl, di(*p*-methoxyphenyl)phenylmethyl, tri(*p*-methoxyphenyl)methyl, 4-(4'-bromophenacyloxy)phenylidiphenylmethyl, 4,4',4''-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4''-tris(levulinoyloxyphenyl)methyl, 4,4',4''-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-ylmethyl)bis(4',4''-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, and 30 benzisothiazolyl S,S-dioxido.

Silyl Ethers

Examples of silyl ethers include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, tri-*p*-xylylsilyl, triphenylsilyl, 5 diphenylmethylsilyl, and *t*-butyldimethoxyphenylsilyl.

Esters

In addition to ethers, a hydroxyl group may be protected as an ester. Examples of esters include formate, benzoylformate, acetate, chloroacetate, 10 dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, *p*-chlorophenoxyacetate, *p*-*P*-phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4-(ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, *p*-phenylbenzoate, 2,4,6-15 trimethylbenzoate(mesitoate)

Carbonates

Examples of carbonates include methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, 2-20 (triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, *p*-nitrophenyl, benzyl, *p*-methoxybenzyl, 3,4-dimethoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, and methyl dithiocarbonate.

Assisted Cleavage

Examples of assisted cleavage include 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate, 4-(methylthiomethoxy)butyrate, and 2-(methylthiomethoxymethyl)benzoate.

Miscellaneous Esters

Examples of miscellaneous esters include 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E)-2-methyl-2-butenoate(tiglate), o-(methoxycarbonyl)benzoate, p-P-benzoate, α -naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, N-phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate

Sulfonates

Examples of sulfonates include sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.

PROTECTION FOR 1,2- AND 1,3-DIOLSCyclic Acetals and Ketals

Examples of cyclic acetals and ketals include methylene, ethylidene, 1-t-butylethylidene, 1-phenylethylidene, (4-methoxyphenyl)ethylidene, 2,2,2-trichloroethylidene, acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, cycloheptylidene, benzylidene, p-methoxybenzylidene, 2,4-dimethoxybenzylidene, 3,4-dimethoxybenzylidene, and 2-nitrobenzylidene.

30

Cyclic Ortho Esters

Examples of cyclic ortho esters include methoxymethylene, ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene, 1-ethoxyethylidene, 1,2-dimethoxyethylidene, α -methoxybenzylidene, 1-(N,N-

dimethylamino)ethylidene derivative, α -(N,N-dimethylamino)benzylidene derivative, and 2-oxacyclopentylidene.

Silyl Derivatives

5 Examples of silyl derivatives include di-*t*-butylsilylene group, and 1,3-(1,1,3,3-tetraisopropylsiloxy) derivative.

AMINO PROTECTING GROUPS

10 Protection for the amino group includes carbamates, amides, and special -NH protective groups.

15 Examples of carbamates include methyl and ethyl carbamates, substituted ethyl carbamates, assisted cleavage carbamates, photolytic cleavage carbamates, urea-type derivatives, and miscellaneous carbamates.

Carbamates

20 Examples of methyl and ethyl carbamates include methyl and ethyl, 9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-di-*t*-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl, and 4-methoxyphenacyl.

Substituted Ethyl

25 Examples of substituted ethyl carbamates include 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1-(4-biphenyl)ethyl, 1-(3,5-di-*t*-butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(N,N-dicyclohexylcarboxamido)ethyl, *t*-butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, N-hydroxypiperidinyl, alkyldithio, benzyl, *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-bromobenzyl, *p*-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthrylmethyl and diphenylmethyl.

Assisted Cleavage

Examples of assisted cleavage include 2-methylthioethyl, 2-methylsulfonyleethyl, 2-(*p*-toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-triphenylphosphonioisopropyl, 1,1-dimethyl-2-cyanoethyl, *m*-chloro-*p*-acyloxybenzyl, *p*-(dihydroxyboryl)benzyl, 5-benzisoxazolylmethyl, and 2-(trifluoromethyl)-6-chromonylmethyl.

Photolytic Cleavage

Examples of photolytic cleavage include *m*-nitrophenyl, 3,5-dimethoxybenzyl, *o*-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl(*o*-nitrophenyl)methyl.

Urea-Type Derivatives

Examples of urea-type derivatives include phenothiazinyl-(10)-carbonyl derivative, N' -*p*-toluenesulfonylaminocarbonyl, and N'-phenylaminothiocarbonyl.

Miscellaneous Carbamates

Examples of miscellaneous carbamates include *t*-amyl, S-benzyl thiocarbamate, *p*-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, *p*-decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, *o*-(*N,N*-dimethylcarboxamido)benzyl, 1,1-dimethyl-3-(*N,N*-dimethylcarboxamido)propyl, 1,1-dimethylpropynyl, di(2-pyridyl)methyl, 2-furanylmethyl, 2-iodoethyl, isobornyl, isobutyl, isonicotinyl, *p*-(*p*'-methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl, 1-methyl-1-(*p*-phenylazophenyl)ethyl, 1-methyl-1-phenylethyl, 1-methyl-1-(4-pyridyl)ethyl, phenyl, *p*-(phenylazo)benzyl, 2,4,6-tri-*t*-butylphenyl, 4-(trimethylammonium)benzyl, and 2,4,6-trimethylbenzyl.

Examples of amides include:

Amides

N-formyl, N-acetyl, N-chloroacetyl, N-trichloroacetyl, N-trifluoroacetyl, N-phenylacetyl, N-3-phenylpropionyl, N-picolinoyl, N-3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, N-benzoyl, N-p-phenylbenzoyl.

5

Assisted Cleavage

N-o-nitrophenylacetyl, N-o-nitrophenoxyacetyl, N-acetoacetyl, (N'-dithiobenzylloxycarbonylamino)acetyl, N-3-(p-hydroxyphenyl)propionyl, N-3-(o-nitrophenyl)propionyl, N-2-methyl-2-(o-nitrophenoxy)propionyl, N-2-methyl-2-(o-phenylazophenoxy)propionyl, N-4-chlorobutyryl, N-3-methyl-3-nitrobutyryl, N-o-nitrocinnamoyl, N-acetylmethionine derivative, N-o-nitrobenzoyl, N-o-(benzoyloxymethyl)benzoyl, and 4,5-diphenyl-3-oxazolin-2-one.

10

Cyclic Imide Derivatives

15

N-phthalimide, N-dithiasuccinoyl, N-2,3-diphenylmaleoyl, N-2,5-dimethylpyrrolyl, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, and 1-substituted 3,5-dinitro-4-pyridonyl.

20

Examples of special NH protective groups include

N-Alkyl and N-Aryl Amines

25

N-methyl, N-allyl, N-[2-(trimethylsilyl)ethoxy]methyl, N-3-acetoxypropyl, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl), quaternary ammonium salts, N-benzyl, N-di(4-methoxyphenyl)methyl, N-5-dibenzosuberyl, N-triphenylmethyl, N-(4-methoxyphenyl)diphenylmethyl, N-9-phenylfluorenyl, N-2,7-dichloro-9-fluorenylmethylene, N-ferrocenylmethyl, and N-2-picolyamine N'-oxide.

30

Imine Derivatives

N-1,1-dimethylthiomethylene, N-benzylidene, N-*p*-methoxybenzylidene, N-diphenylmethylene, N-[(2-pyridyl)mesityl]methylene, and N-(N',N'-dimethylaminomethylene).

5

PROTECTION FOR THE CARBONYL GROUP

Acyclic Acetals and Ketals

Examples of acyclic acetals and ketals include dimethyl, bis(2,2,2-trichloroethyl), dibenzyl, bis(2-nitrobenzyl) and diacetyl.

Cyclic Acetals and Ketals

15 Examples of cyclic acetals and ketals include 1,3-dioxanes, 5-methylene-1,3-dioxane, 5,5-dibromo-1,3-dioxane, 5-(2-pyridyl)-1,3-dioxane, 1,3-dioxolanes, 4-bromomethyl-1,3-dioxolane, 4-(3-butenyl)-1,3-dioxolane, 4-phenyl-1,3-dioxolane, 4-(2-nitrophenyl)-1,3-dioxolane, 4,5-dimethoxymethyl-1,3-dioxolane, *O,O'*-phenylenedioxy and 1,5-dihydro-3H-2,4-benzodioxepin.

Acyclic Dithio Acetals and Ketals

20 Examples of acyclic dithio acetals and ketals include S,S'-dimethyl, S,S'-diethyl, S,S'-dipropyl, S,S'-dibutyl, S,S'-dipentyl, S,S'-diphenyl, S,S'-dibenzyl and S,S'-diacetyl.

Cyclic Dithio Acetals and Ketals

25 Examples of cyclic dithio acetals and ketals include 1,3-dithiane, 1,3-dithiolane and 1,5-dihydro-3H-2,4-benzodithiepin.

Acyclic Monothio Acetals and Ketals

Examples of acyclic monothio acetals and ketals include O-trimethylsilyl-S-alkyl, O-methyl-S-alkyl or -S-phenyl and O-methyl-S-2-(methylthio)ethyl.

Cyclic Monothio Acetals and Ketals

Examples of cyclic monothio acetals and ketals include 1,3-oxathiolanes.

MISCELLANEOUS DERIVATIVES

5

O-Substituted Cyanohydrins

Examples of O-substituted cyanohydrins include O-acetyl, O-trimethylsilyl, O-1-ethoxyethyl and O-tetrahydropyranyl.

10

Substituted Hydrazones

Examples of substituted hydrazones include N,N-dimethyl and 2,4-dinitrophenyl.

15

Oxime Derivatives

Examples of oxime derivatives include O-methyl, O-benzyl and O-phenylthiomethyl.

20

Imines

Substituted Methylene Derivatives, Cyclic Derivatives

Examples of substituted methylene and cyclic derivatives include oxazolidines, 1-methyl-2-(1'-hydroxyalkyl)imidazoles, N,N'-dimethylimidazolidines, 2,3-dihydro-1,3-benzothiazoles, diethylamine adducts, and methylaluminum bis(2,6-di-*t*-butyl-4-methylphenoxyde)(MAD)complex.

25

MONOPROTECTION OF DICARBONYL COMPOUNDS

Selective Protection Of α -and β -Diketones

Examples of selective protection of α -and β -diketones include enamines, enol acetates, enol ethers, methyl, ethyl, *i*-butyl, piperidinyl, morpholinyl, 4-methyl-1,3-dioxolanyl, pyrrolidinyl, benzyl, S-butyl, and trimethylsilyl.

Cyclic Ketals, Monothio and Dithio Ketals

Examples of cyclic ketals, monothio and dithio ketals include bismethylenedioxy derivatives and tetramethylbismethylenedioxy derivatives.

5

PROTECTION FOR THE CARBOXYL GROUPEsters10 Substituted Methyl Esters

Examples of substituted methyl esters include 9-fluorenylmethyl, methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, phenacyl, *p*-bromophenacyl, α -methylphenacyl, *p*-methoxyphenacyl, 15 carboxamidomethyl, and N-phthalimidomethyl.

2-Substituted Ethyl Esters

Examples of 2-substituted ethyl esters include 2,2,2-trichloroethyl, 2-haloethyl, ω -chloroalkyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl, 1,3-20 dithianyl-2-methyl, 2-(*p*-nitrophenylsulfenyl)ethyl, 2-(*p*-toluenesulfonyl)ethyl, 2-(2'-pyridyl)ethyl, 2-(diphenylphosphino)ethyl, 1-methyl-1-phenylethyl, *t*-butyl, cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl, α -methylcinnamyl, phenyl, *p*-(methylmercapto)phenyl and benzyl.

25 Substituted Benzyl Esters

Examples of substituted benzyl esters include triphenylmethyl, diphenylmethyl, bis(*o*-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-dibenzosuberyl, 1-pyrenylmethyl, 2-(trifluoromethyl)-6-chromylmethyl, 2,4,6-trimethylbenzyl, *p*-bromobenzyl, *o*-nitrobenzyl, *p*-30 nitrobenzyl, *p*-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfobenzyl, piperonyl, 4-picoly and *p*-P-benzyl.

Silyl Esters

Examples of silyl esters include trimethylsilyl, triethylsilyl, *t*-butyldimethylsilyl, *i*-propyldimethylsilyl, phenyldimethylsilyl and di-*t*-butyldimethylsilyl.

5 Activated Esters

Examples of activated esters include thiols.

Miscellaneous Derivatives

10 Examples of miscellaneous derivatives include oxazoles, 2-alkyl-1,3-oxazolines, 4-alkyl-5-oxo-1,3-oxazolidines, 5-alkyl-4-oxo-1,3-dioxolanes, ortho esters, phenyl group and pentaaminocobalt(III) complex.

Stannylic Esters

Examples of stannylic esters include triethylstannyl and tri-*n*-butylstannyl.

15

Amides

Examples of amides include N,N-dimethyl, pyrrolidinyl, piperidinyl, 5,6-dihydrophenanthridinyl, *o*-nitroanilides, N-7-nitroindolyl, N-8-Nitro-1,2,3,4-tetrahydroquinolyl, and *p*-P-benzenesulfonamides.


20

Hydrazides

Examples of hydrazides include N-phenyl and N,N'-diisopropyl.

E. Chemical Examples

EXAMPLE 1

 $K_i = 0.005 \mu M$ 

5

(5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone


A mixture of 5-chloroindole-2-carboxylic acid (0.234 g), HATU (0.569 g), HOAT (0.203 g) and N, N-diisopropylethylamine (0.191 mL) in DMF (0.6 mL) was
10 treated with N-methylpiperazine (0.1 mL) stirred at ambient temperature for 48 h then concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with 1 M hydrochloric acid, saturated sodium hydrogen carbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (3-10% 2 M ammonia in methanol/dichloromethane) to give the title compound (0.18 g). 1H NMR (400 MHz, $CDCl_3$): δ 9.60 (br s, 1H), 7.65 (d, $J = 1.5$ Hz, 1H), 7.40 (d, $J = 8.6$ Hz, 1H), 7.29 (d, $J = 2.0$ Hz, 1H), 7.26 (d, 1.8 Hz, 1H), 6.76 (d, $J = 1.5$ Hz, 1H), 4.0 (br m, 4H), 2.56 (t, $J = 5.1$ Hz, 4H), 2.41 (s, 3H). Analysis: Calc'd for $C_{14}H_{18}ClN_3O$; C, 60.54; H, 5.81; N, 15.13;
15 20 Found: C, 59.99; H, 5.94; N, 18.87.

The title compounds of the following examples (2-14) were prepared according to the general procedure of Scheme 1, as indicated for Example 1.

EXAMPLE 2

5

$K_i = 0.018 \mu\text{M}$




(5-Fluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 9.70 (br s, 1H), 7.33 (m, 2H), 7.09-6.98 (m, 1H),
10 6.75 (m, 1H), 3.97 (br m, 4H), 2.53 (dm, $J = 4.7$ Hz, 4H), 2.38 (s, 3H).

EXAMPLE 3

15

$K_i = 0.008 \mu\text{M}$




(5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 9.65 (br s, 1H), 7.78 (d, $J = 1.0$ Hz, 1H), 7.40-
7.26 (m, 2H), 6.73 (d, $J = 2.3$ Hz, 1H), 3.97 (br m, 4H), 2.53 (t, $J = 5.1$ Hz, 4H),
20 2.37 (s, 3H).

EXAMPLE 4

$K_i = 0.117 \mu\text{M}$




(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃/CD₃OD): δ 7.63-7.56 (m, 1H), 7.40 (dt, J = 1.0, 8.3 Hz, 1H), 7.26-7.20 (m, 1H), 7.11-7.05 (m, 1H), 6.99 (d, J = 0.8 Hz), 6.72 (d, J = 0.8 Hz), 3.88 (br m, 4H), 2.48 (t, J = 5.1 Hz, 4H), 2.31 (s, 3H).


EXAMPLE 5

10

 $K_i = 7 \mu\text{M}$ 

(5-Benzyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

EXAMPLE 6

 $K_i = 0.011 \mu M$ 


(5-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

5

¹H NMR (400 MHz, CDCl₃): δ 8.91 (br s, 1H), 7.34 (dm, J = 0.7 Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.04 (dd, J = 8.3, 1.3 Hz, 1H), 6.62 (dd, J = 2.0, 0.8 Hz, 1H), 3.88 (br m, 4H), 2.44 (t, J = 4.0 Hz, 4H), 2.37 (s, 3H), 2.29 (s, 3H).

10


EXAMPLE 7

 $K_i = 10 \mu M$ 

(5,6-Dimethoxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

15

EXAMPLE 8


 $K_i = 2 \mu M$ 

20

(4-Methyl-piperazin-1-yl)-(7-nitro-1H-indol-2-yl)-methanone


¹H NMR (400 MHz, CDCl₃): δ 10.46 (br s, 1H), 8.29 (d, 1H), 8.06 (d, 1H), 7.34 (m, 1H), (t, 1H), 3.94 (br m, 4H), 2.54 (t, 4H), 2.40 (s, 3H).

EXAMPLE 9

 $K_i = 10 \mu M$ 

5 (4-Methyl-piperazin-1-yl)-(5-nitro-3-phenyl-1H-indol-2-yl)-methanone


EXAMPLE 10

 $K_i = 1.7 \mu M$ 

10

(4-Methyl-piperazin-1-yl)-(5-trifluoromethoxy-1H-indol-2-yl)-methanone

EXAMPLE 11


 $K_i = 0.124 \mu M$ 

15

(6-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 10.14 (br s, 1H), δ 7.55 (d, J = 8.3 Hz, 1H), 7.44
 20 (t, J = 1.0 Hz, 1H), 7.10 (dd, J = 8.3, 1.8 Hz, 1H), 6.76 (dd, J = 2.3, 1.0 Hz, 1H),
 4.00 (br m, 4H), 2.54 (t, J = 5.1 Hz, 4H), 2.38 (s, 3H). MS: exact mass
 calculated for C₁₄H₁₆ClN₃O, 277.10; m/z found, 278.1 [M+H]⁺.


EXAMPLE 12

 $K_i = 0.019 \mu M$ 

5 (5,7-Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 9.94 (br s, 1H), 7.10 (dd, J = 8.8, 2.0 Hz, 1H), 6.87-6.78 (m, 1H), 6.77 (t, J = 2.8 Hz, 1H), 3.97 (br m, 4H), 2.53 (t, J = 5.1 Hz, 4H), 2.37 (s, 3H). MS: exact mass calculated for C₁₄H₁₅F₂N₃O, 279.12; m/z 10 found, 280 [M+H]⁺.

EXAMPLE 13


 $K_i = 0.235 \mu M$ 

15 (6-Fluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 9.45 (br s, 1H), 7.49 (dd, J = 8.8, 5.6 Hz, 1H), 7.02 (dd, J = 9.4, 2.3 Hz, 1H), 6.87-6.81 (m, 1H), 6.69 (dd, J = 2.0, 1.0 Hz, 1H), 3.89 (br m, 4H), 2.44 (t, J = 5.1 Hz, 4H), 2.88 (s, 3H).

EXAMPLE 14

 $K_i = 3 \mu M$




(4,6-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

5

EXAMPLE 15

$$K_i = 2 \mu\text{M}$$



(1H-Indol-2-yl)-(4-octyl-piperazin-1-yl)-methanone


10 Indole-2-carboxylic acid (0.193 g) in THF (25 mL) was treated with carbonyldiimidazole (0.178 g) and stirred at ambient temperature for 2 h whereupon 1-octyl-piperazine (0.142 g) was added. The mixture was stirred at ambient temperature for 18 h, and the solvent removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with

15 saturated sodium bicarbonate solution, and the organic portion was separated, dried over sodium sulfate and filtered. Solvent was evaporated to afford the title compound (0.28 g). ^1H NMR (400 MHz, CD_3OD): δ 7.50 (d, $J = 8.0$ Hz, 1H), 7.32 (d, $J = 8.3$ Hz, 1H), 7.13 – 7.09 (m, 1H), 6.98 – 6.94 (m, 1H), 6.71 (s, 1H), 3.79 (s, 4H), 2.46 (t, $J = 4.7$ Hz, 4H), 2.32 (t, $J = 7.7$ Hz, 2H), 1.46 (br s, 2H), 1.36 – 1.03 (m, 12H), 0.82 – 0.79 (m, 3H).

The title compounds of the following examples (16-38) were prepared according to the general procedure of Scheme 1, as indicated for Example 15.

EXAMPLE 16


5

 $K_i = 3 \mu\text{M}$ 

(4-Ethyl-piperazin-1-yl)-(1H-indol-2-yl)-methanone

10


EXAMPLE 17

 $K_i = 5 \mu\text{M}$ 

(1H-Indol-2-yl)-(4-isopropyl-piperazin-1-yl)-methanone

15


EXAMPLE 18

 $K_i = 5 \mu\text{M}$ 

20

[4-(3-Dimethylamino-propyl)-piperazin-1-yl]-(1H-indol-2-yl)-methanone


EXAMPLE 19

$K_i = 7 \mu\text{M}$ 

(4-Butyl-piperazin-1-yl)-(1H-indol-2-yl)-methanone

5


EXAMPLE 20

 $K_i = 7 \mu\text{M}$ 

(4-Cyclopentyl-piperazin-1-yl)-(1H-indol-2-yl)-methanone

10

EXAMPLE 21


 $K_i = 7 \mu\text{M}$ 

15

(1H-Indol-2-yl)-(4-phenethyl-piperazin-1-yl)-methanone

EXAMPLE 22


 $K_i = 7 \mu\text{M}$



(1H-Indol-2-yl)-[4-(2-piperidin-1-yl-ethyl)-piperazin-1-yl]-methanone

5


EXAMPLE 23

 $K_i = 8 \mu\text{M}$ 

[4-(2-Ethoxy-ethyl)-piperazin-1-yl]-[1H-indol-2-yl]-methanone

10

EXAMPLE 24


 $K_i = 8 \mu\text{M}$ 

(4-sec-Butyl-piperazin-1-yl)-(1H-indol-2-yl)-methanone

15

EXAMPLE 25

 $K_i = 8 \mu\text{M}$




[4-(1-Ethyl-propyl)-piperazin-1-yl]-(1H-indol-2-yl)-methanone

5

EXAMPLE 26

$K_i = 8 \mu\text{M}$




(1H-Indol-2-yl)-[4-(3-phenyl-propyl)-piperazin-1-yl]-methanone

10

EXAMPLE 27

$K_i = 8 \mu\text{M}$




(1H-Indol-2-yl)-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-methanone

15

EXAMPLE 28

$K_i = 8 \mu\text{M}$




[4-(2-Dipropylamino-ethyl)-piperazin-1-yl]-(1H-indol-2-yl)-methanone

5

EXAMPLE 29

$K_i = 10 \mu\text{M}$




(1H-Indol-2-yl)-[4-(3-phenyl-allyl)-piperazin-1-yl]-methanone

10

EXAMPLE 30

$K_i = 9 \mu\text{M}$




(1H-Indol-2-yl)-(4-pentyl-piperazin-1-yl)-methanone

15

EXAMPLE 31


$K_i = 9 \mu\text{M}$



(4-Heptyl-piperazin-1-yl)-(1H-indol-2-yl)-methanone

EXAMPLE 32


5

 $K_i = 9 \mu M$ 

(4-(2-Diethylamino-ethyl)-piperazin-1-yl)-(1H-indol-2-yl)-methanone

10


EXAMPLE 33

 $K_i = 9 \mu M$ 

(1H-Indol-2-yl)-[4-(4-methoxy-butyl)-piperazin-1-yl]-methanone

15

EXAMPLE 34


 $K_i = 9 \mu M$ 

(4-Allyl-piperazin-1-yl)-(1H-indol-2-yl)-methanone

20

EXAMPLE 35

 $K_i = 9 \mu M$




[4-(2-Dimethylamino-ethyl)-piperazin-1-yl]-(1H-indol-2-yl)-methanone

5

EXAMPLE 36

$K_i = 10 \mu\text{M}$




(1H-Indol-2-yl)-[4-(1-methyl-piperidin-3-yl)-piperazin-1-yl]-methanone

10

EXAMPLE 37

$K_i = 0.1 \mu\text{M}$



(1H-Indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone


15

^1H NMR (400 MHz, CDCl_3): δ 9.16 (s, 1H), 7.65 (d, $J = 7.9 \text{ Hz}$, 1H), 7.42 (d, $J = 8.3 \text{ Hz}$, 1H), 7.30-7.25 (m, 1H), 7.14 (t, $J = 7.2 \text{ Hz}$, 1H), 6.77 (s, 1H), 4.59 (m, 2H), 3.10 (m, 1H), 2.94-2.86 (m, 2H), 1.65 (s, 3H), 1.14 (d, $J = 5.6 \text{ Hz}$, 3H).

20

EXAMPLE 38

$K_i = 10 \mu\text{M}$




(1-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

10 ^1H NMR (400 MHz, CDCl_3): δ 7.64 (dt, J = 1.0, 7.8 Hz, 1H), 7.38 (dd, J = 8.3, 0.8 Hz, 1H), 7.35-7.32 (m, 1H), 7.19-7.14 (m, 1H), 6.62 (d, J = 0.8 Hz, 1H), 3.86 (s, 3H), 3.83 (br m, 4H), 2.49 (br m, 4H), 2.37 (s, 3H).

EXAMPLE 39

10

 K_i = 0.023 μM 

(7-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

15 2-Chlorophenylhydrazine hydrochloride (0.5 g) in ethanol (25 mL) was treated with ethylpyruvate (0.324 g) and concentrated sulfuric acid (3 drops). The mixture was stirred at ambient temperature for five min and treated with polyphosphoric acid (0.5 g). The mixture was heated at reflux temperature for 24 h wheréupon additional polyphosphoric acid (0.5 g) was added and heating continued for a further 48 h. The reaction mixture was cooled to ambient

20 temperature and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water and the pH of the aqueous layer adjusted to neutrality by addition of saturated sodium hydrogen carbonate solution. The organic fraction was separated, washed with brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified via

25 silica gel chromatography (5-10% ethyl acetate/hexane) to give 7-Chloro-1H-indole-2-carboxylic acid ethyl ester (0.227 g). This material (0.102 g) was used without further purification. The ester was treated with 1 M lithium hydroxide in


ethanol (5 mL) followed by water (3 mL) and stirred at ambient temperature for 18 h. The solution was acidified with 10% hydrochloric acid, diluted with water and extracted with ethyl acetate. The organic extracts were washed with brine, dried over magnesium sulfate, filtered, and concentrated to afford give 7-
 5 Chloro-1H-indole-2-carboxylic acid (0.089 g). This material (0.089 g), was treated with HATU (0.259 g), HOAT (0.093 g), N, N-diisopropylethylamine (0.158 mL) and N-methylpiperazine (0.05 mL) in DMF (0.6 mL) and stirred at ambient temperature for 18 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with 1
 10 M hydrochloric acid, saturated sodium hydrogencarbonate solution and then brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (2-10% 2 M ammonia in methanol/dichloromethane) to give the title compound (0.56 g). ¹H NMR (400 MHz, CDCl₃): δ 9.17 (br s, 1H), 7.47 (d, J = 8.1 Hz, 1H), 7.21 (dd, J = 7.6, 0.8 Hz, 1H), 7.01 (t, J = 7.8 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H), 3.88 (br m, 4H), 2.45 (t, J = 5.1 Hz, 4H), 2.29 (s, 3H).
 15

The title compounds of the following examples (40-43) were prepared according to the general procedure of Scheme 2, as indicated for example 39.

20

EXAMPLE 40

K_i = 0.010 μM




25

¹H NMR (400 MHz, CDCl₃): δ 9.08 (br s, 1H), 7.36 (dd, J = 1.8, 0.8 Hz, 1H), 7.12 (d, J = 1.8 Hz, 1H), 6.56 (d, J = 2.3 Hz, 1H), 3.77 (br m, 4H), 2.34 (t, J = 5.1 Hz, 4H), 2.20 (s, 3H).

30


EXAMPLE 41

 $K_i = 0.040 \mu\text{M}$ 

(4-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

5

EXAMPLE 42


 $K_i = 0.188 \mu\text{M}$ 

10 (6-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 9.70 (br s, 1H), 7.69 (t, $J = 0.8$ Hz, 1H), 7.51 (d, $J = 8.6$ Hz, 1H), 7.24 (dd, $J = 8.6, 1.8$ Hz, 1H), 6.76 (dd, $J = 2.0, 1.0$ Hz, 1H), 3.98 (br m, 4H), 2.54 (t, $J = 5.1$ Hz, 4H), 2.37 (s, 3H).

15

EXAMPLE 43

 $K_i = 0.055 \mu\text{M}$ 

20 (7-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone


¹H NMR (400 MHz, CDCl₃): δ 9.06 (br s, 1H), 7.51 (dt, $J = 0.8, 8.1$ Hz, 1H), 7.36 (dd, $J = 7.7, 0.8$ Hz, 1H), 6.96 (t, $J = 7.8$ Hz, 1H), 6.76 (d, $J = 2.3$ Hz, 1H),

3.87 (br m, 4H), 2.43 (t, J = 5.1 Hz, 4H), 2.28 (s, 3H). MS: exact mass calculated for $C_{14}H_{16}BrN_3O$, 321.05; m/z found, 322.1 [M+H]⁺.

The title compound of the following example (44) was prepared according to
5 the general procedure of Scheme 3.

EXAMPLE 44

K_i = 0.095 μ M




10 (5-Bromo-benzofuran-2-yl)-(4-methyl-piperazin-1-yl)-methanone

5-Bromo-benzofuran-2-carboxylic acid (0.346 g) in THF (7 mL) was treated with carbonyldiimidazole (0.214 g) and stirred at ambient temperature for 2 h whereupon methyl-piperazine (0.129 g) was added. The mixture was stirred at 15 ambient temperature for 18 h and then concentrated under reduced pressure. The residue was dissolved in dichloromethane and washed with saturated sodium bicarbonate solution, whereupon the organic portion was separated out, dried over sodium sulfate and filtered. The solvent was evaporated, and the residue was purified via silica gel chromatography (5% 2M ammonium in 20 methanol/dichloromethane) to afford the title compound (0.222g). ¹H NMR (400 MHz, $CDCl_3$): δ 7.75 (d, J = 1.9 Hz, 1H), 7.45 (dd, J = 8.8, 1.9 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 3.83 (br s, 4H), 2.48 (t, J = 4.8 Hz, 4H), 2.33 (s, 3H). ¹³C NMR (400 MHz, $CDCl_3$) δ 159.4, 153.4, 150.3, 129.6, 129.0, 124.9, 116.8, 113.5, 111.3, 55.3, 54.9, 46.8, 46.1, 42.9.

25

EXAMPLE 45

K_i = 10 μ M



Indole-2-carboxylic acid (5.2 g) in THF (200 mL) was treated with carbonyldiimidazole (4.8 g) and stirred at ambient temperature for 10 min whereupon 4-methyl-piperazine-1-carboxylic acid tert-butyl ester (5.0 g) was added. The mixture was stirred at ambient temperature for 72 h and the solvent removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution. The organic portion was separated, dried over sodium sulfate and filtered, and solvent was evaporated to afford a solid. Recrystallization from hot ethanol afforded 4-(1H-Indole-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester (4.2 g).


4-(1H-Indole-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester (0.165 g) in dichloromethane (10 mL) was treated with trifluoroacetic acid (2 mL) and stirred at ambient temperature for 1 h. The solvent was removed under reduced pressure to afford (1H-Indol-2-yl)-piperazin-1-yl-methanone trifluoroacetate salt. (¹H NMR (400 MHz, CDCl₃): δ 7.63 (d, J = 8.07 Hz, 1H), 7.44 (dd, J = 8.3, 0.8 Hz, 1H), 7.24 (m, 1H), 7.08 (m, 1H), 6.91 (s, 1H), 4.12 (t, J = 5.0 Hz, 4H), 3.35 (t, J = 5.3 Hz, 4H)). This intermediate was dissolved in acetone (5 mL), treated with potassium carbonate (0.22 g), iodohexane (0.106 g) and heated at 50° C for 10 h. Evaporation of the solvent under reduced pressure afforded crude product which was purified via preparative thin layer chromatography eluting with 10% methanol/dichloromethane to give the title compound (0.06 g). ¹H NMR (400 MHz, CD₃OD): δ 7.60 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.21 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.16 – 7.04 (m, 1H), 6.81 (s, 1H), 3.89 (br s, 4H), 2.56 (t, J = 5.0 Hz, 4H), 2.43 – 2.40 (m, 2H), 1.58 – 1.52 (m, 2H), 1.34 (br s, 6H), 0.94 – 0.90 (m, 3H).

The title compounds of the following examples (46-47) were prepared according to the general procedure of Scheme 5, as indicated for Example 74.

EXAMPLE 46

5

$K_i = 10 \mu\text{M}$




[4-(2-Cyclohexyl-ethyl)-piperazin-1-yl]-(1H-indol-2-yl)-methanone

EXAMPLE 47

10

$K_i = 10 \mu\text{M}$




(1H-Indol-2-yl)-[4-(4-methyl-pentyl)-piperazin-1-yl]-methanone

15

EXAMPLE 48

$K_i = 3 \mu\text{M}$




20

(3-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4, 0.222 g) in acetic acid (1 mL) at ambient temperature was treated with bromine (0.05 mL) and stirred for 7 h. The reaction mixture was poured into water and adjusted to basic pH by addition of 1 M sodium hydroxide. The mixture was extracted with dichloromethane. The organic extracts were combined, dried over sodium sulfate, filtered, and concentrated to give crude product. Purification via silica gel chromatography, eluting with 1-8% methanol/dichloromethane, afforded the title compound (0.154 g).

10

EXAMPLE 49

 $K_i = 3 \mu\text{M}$ 

(3,5-Dibromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone


15

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4, 0.222 g) in acetic acid (1 mL) at ambient temperature was treated with bromine (0.10 mL) and stirred for 7 h. The reaction mixture was poured into water and adjusted to basic pH by addition of 1 M sodium hydroxide. The mixture was extracted with dichloromethane. The organic extracts were combined, dried over sodium sulfate, filtered, and concentrated to give crude product. Purification via silica gel chromatography, eluting with 1-8% methanol/dichloromethane afforded the title compound (0.123 g).

25

EXAMPLE 50

 $K_i = 9 \mu\text{M}$




(4-Methyl-piperazin-1-yl)-(3,5,7-tribromo-1H-indol-2-yl)-methanone

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4, 0.222 g) in 5 acetic acid (1 mL) at ambient temperature was treated with bromine (0.15 mL) and stirred for 7 h. The reaction mixture was poured into water and adjusted to basic pH by addition of 1 M sodium hydroxide. The mixture was extracted with dichloromethane. The organic extracts were combined, dried over sodium sulfate, filtered, and concentrated to give crude product. Purification via silica 10 gel chromatography, eluting with 1-8% methanol/dichloromethane afforded the title compound (0.038 g).

EXAMPLE 51

15 $K_i = 7 \mu\text{M}$




2-(4-Methyl-piperazine-1-carbonyl)-1H-indole-3-carbaldehyde

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4, 0.206 g) in 20 DMF (1.5 mL) at 0° C was treated with phosphorus oxychloride (0.1 mL) over 10 min. The reaction mixture was warmed to ambient temperature and stirred for 16 h. The reaction mixture was poured into water and adjusted to neutral pH by addition of 1 M sodium hydroxide. The mixture was extracted with dichloromethane. The organic extracts were combined, dried over sodium 25 sulfate, filtered, and concentrated to give crude product. Purification via silica

gel chromatography, eluting with 1-8% methanol/dichloromethane afforded the title compound (0.108 g).

5

EXAMPLE 52

 $K_i = 10 \mu\text{M}$ 


(3-Hydroxymethyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

10 2-(4-Methyl-piperazine-1-carbonyl)-1H-indole-3-carbaldehyde (Example 51, 0.094 g) in ethyl acetate (1.5 mL) was treated with sodium borohydride (0.024 g) and stirred at ambient temperature for 3 h. The solvent was removed under reduced pressure, and the residue treated with saturated sodium hydrogencarbonate solution and extracted with dichloromethane. The organic extracts were dried over sodium sulfate, filtered, and concentrated. The residue was purified via silica gel chromatography, eluting with 1-8% methanol/dichloromethane, to afford the title compound (0.042 g).

15

20

EXAMPLE 53


 $K_i = 9 \mu\text{M}$ 

(4-Methyl-piperazin-1-yl)-(3-pyrrolidin-1-ylmethyl-1H-indol-2-yl)-methanone

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4, 0.231 g) in acetic acid (1.5 mL) at ambient temperature was treated with paraformaldehyde (0.4 g) and pyrrolidine (0.16 mL). The reaction mixture was heated at 60° for 6 h then poured into water and the solution adjusted to basic 5 pH by addition of 1 M sodium hydroxide. The mixture was extracted with dichloromethane. The organic extracts were combined, dried over sodium sulfate, filtered, and concentrated to give crude product. Purification via silica gel chromatography, eluting with 1-8% methanol/dichloromethane afforded the title compound (0.1 g).

10

EXAMPLE 54


 $K_i = 0.378 \mu\text{M}$ 

15 (3-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4, 0.5 g) in dichloromethane (3 mL) at ambient temperature was treated with N-chlorosuccinimide (0.301 g) and stirred for 6 h. The reaction mixture was 20 diluted with ether, washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated to give crude product. Purification via silica gel chromatography, eluting with 1-8% methanol/dichloromethane, afforded the title compound (0.36 g). ^1H NMR (400 MHz, CDCl_3): δ 2.36 (3H), 2.52 (4H), 3.79 (4H), 7.21 (1H), 7.31 (1H), 7.38 (1H), 7.64 (1H), 9.05 (1H).

EXAMPLE 55

 $K_i = 7.0 \mu\text{M}$




(3,5-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

(5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 1, 0.23 g) in dichloromethane (3 mL) at ambient temperature was treated with N-chlorosuccinimide (0.123 g) and stirred for 18 h. The reaction mixture was diluted with ether, washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated to give crude product. Purification via silica gel chromatography, eluting with 1-8% methanol/dichloromethane afforded the title compound (0.13 g). ^1H NMR (400 MHz, CDCl_3): δ 2.36 (3H), 2.53 (4H), 3.79 (4H), 7.22 (1H), 7.29 (1H), 7.58 (1H), 10.39 (1H).

15

EXAMPLE 56

 $K_i = 0.238 \mu\text{M}$ 


(5-Bromo-3-chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

(5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 3, 0.27 g) in dichloromethane (3 mL) at ambient temperature was treated with N-chlorosuccinimide (0.103 g) and stirred for 18 h. The reaction mixture was diluted with ether, washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated to give crude product. Purification via silica gel chromatography, eluting with 1-8% methanol/dichloromethane afforded the title compound (0.16 g). ^1H NMR

(400 MHz, CDCl_3): δ 2.35 (3H), 2.52 (4H), 3.78 (4H), 7.23 (1H), 7.35 (1H), 7.74 (1H), 9.84 (1H).

5


EXAMPLE 57

 $K_i = 9 \mu\text{M}$ 

(3-Dimethylaminomethyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

10 The title compound was prepared from (1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4) according to the general procedure of Example 53 (See: *J. Am. Chem. Soc.*, **71**:3541, 1949). ^1H NMR (400 MHz, CDCl_3): δ 9.39 (br, 1H), 7.78 (m, 1H), 7.34 (m, 1H), 7.21 (m, 1H), 7.11 (m, 1H), 5.28 (s, 2H), 3.69 (br, 4H), 2.40 (br, 4H), 2.29 (s, 3H), 2.24 (s, 6H)). MS (electrospray):
 15 exact mass calculated for $\text{C}_{17}\text{H}_{24}\text{N}_4\text{O}$, 300.20; m/z found, 301.1 $[\text{M}+\text{H}]^+$.

EXAMPLE 58

 $K_i = 0.132 \mu\text{M}$ 

20

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanethione

(1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 4, 0.123 g) in THF (1 mL) was treated with Lawesson's reagent (0.243 g) and stirred at 25 ambient temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified via preparative thin layer


chromatography to afford the title compound (0.02 g). ^1H NMR (400 MHz, CDCl_3): δ 9.21 (br s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.29 (d, J = 7.3 Hz, 1H), 7.12 (m, 1H), 6.60 (s, 1H), 4.39 (br s, 4H), 3.85 (br s, 4H), 2.63 (s, 3H).

5

The title compounds of the following examples (59 and 60) were prepared according to the general procedure of Scheme 1.

10

EXAMPLE 59

 K_i = 46 nM

(4-Methyl-piperazin-1-yl)-(5-nitro-1H-indol-2-yl)-methanone

15 A mixture of 5-nitroindole-2-carboxylic acid (4.38 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 4.89 g) in dichloromethane (150 mL) was treated with N-methylpiperazine (2.83 mL) and stirred at ambient temperature for 16 h. The reaction mixture was poured into dichloromethane (200 mL), washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-10% 2M ammonia in methanol/dichloromethane) to give the title compound (1.8 g). ^1H NMR (400 MHz, CDCl_3): δ 10.97 (br s, 1H), 8.58 (d, J = 2.15 Hz, 1H), 8.11 (dd, J = 2.15, 7.04 Hz, 1H), 7.44 (d, J = 9.00 Hz, 1H), 6.89 (s, 1H), 3.95 (br m, 4H), 2.52 (t, J = 4.89 Hz, 4H), 2.34 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{14}\text{H}_{16}\text{N}_4\text{O}_3$, 288.12; m/z found, 289.1 $[\text{M}+\text{H}]^+$.


20

25

30

EXAMPLE 60

$K_i = 6.6 \text{ nM}$



(7-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone


5 A mixture of 7-methylindole-2-carboxylic acid (1.79 g, 10 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 2.88 g, 15 mmol) in CH_2Cl_2 (100 mL) was treated with N-methylpiperazine (2.22 mL, 20 mmol). The reaction mixture was stirred at ambient temperature for 16 h and then concentrated under reduced pressure. The residue was dissolved in
 10 CH_2Cl_2 (100 mL), washed with water (25 mL X2) and then brine (25 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. This product was purified via silica gel chromatography (5-10% methanol/dichloromethane) to give the title compound as a white solid (2.5 g, 97.3%). ^1H NMR (400 MHz, CDCl_3): δ 11.07 (br s, 1H), 7.43 (d, $J = 7.04 \text{ Hz}$, 1H), 7.00-6.92 (m, 2H), 6.71 (d, $J = 1.96 \text{ Hz}$, 1H), 3.86 (br s, 4H), 2.37 (s, 3H), 2.35-2.28 (m, 4H), 2.19 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{15}\text{H}_{19}\text{N}_3\text{O}$, 257.15; m/z found, 258.2 $[\text{M}+\text{H}]^+$.

15

20

EXAMPLE 61

$K_i = 19 \text{ nM}$




(5-Amino-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

25 The product of Example 59, (4-Methyl-piperazin-1-yl)-(5-nitro-1H-indol-2-yl)-methanone (1.8 g) was dissolved in CH_3OH (50 mL). At room temperature, ammonium formate (3.94 g) was added, followed by 10% palladium on carbon

(0.66 g). The reaction mixture was heated to reflux for forty min, cooled and filtered through celite pad. The filtrate was concentrated and the residue was purified via silica gel chromatography (3-10% 2 M ammonia in methanol/dichloromethane) to give the title compound (1.60 g). ¹H NMR (400 MHz, CDCl₃): δ 10.46 (br s, 1H), 7.12 (d, J = 8.80 Hz, 1H), 6.81 (d, J = 2.15 Hz, 1H), 6.64 (dd, J = 2.15, 6.46 Hz, 1H), 6.54 (d, J = 1.37 Hz, 1H), 3.88 (br m, 4H), 3.70 (br s, 2H), 2.40 (t, J = 4.70 Hz, 4H), 2.25 (s, 3H). MS (electrospray): exact mass calculated for C₁₄H₁₈N₄O, 258.15; m/z found, 259.1 [M+H]⁺.

10

EXAMPLE 62

 $K_i = 7$ nM


(7-Amino-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

15

The product of Example 8, (4-Methyl-piperazin-1-yl)-(7-nitro-1H-indol-2-yl)-methanone (6.4 g, 22.2 mmol), was dissolved in CH₃OH (110 mL). At room temperature, ammonium formate (14.0 g, 222 mmol) was added, followed by 10% palladium on carbon (2.4 g, 2.22 mmol). The reaction mixture was heated to reflux for forty min, cooled, and then filtered through a celite pad. The filtrate was concentrated, and the residue was purified via silica gel chromatography (3-10% 2 M ammonia in methanol/dichloromethane) to give the title compound (4.4 g, 76.7%) as an off- white solid. ¹H NMR (400 MHz, CDCl₃/CD₃OD): δ 7.08 (d, J = 7.83 Hz, 1H), 6.94 (t, J = 7.83 Hz, 1H), 6.73 (s, 1H), 6.58 (d, J = 7.63 Hz, 1H), 4.12 (s, 2H), 3.92 (br s, 4H), 2.51 (br s, 4H), 2.34 (s, 3H). MS (electrospray): exact mass calculated for C₁₄H₁₈N₄O, 258.15; m/z found, 259.1 [M+H]⁺.

The title compounds of the following examples (63 through 66) were prepared according to the general procedure of Scheme 1.

EXAMPLE 63

 $K_i = 32.5 \text{ nM}$ 


5 (6-Hydroxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

6-Methoxy-1H-indole-2-carboxylic acid ethyl ester (5.0 g) was treated with lithium hydroxide (2.33 g) in THF (90 mL) followed by water (30 mL) and stirred at ambient temperature for 16 h. The solution was acidified with 10% hydrochloric acid, diluted with water and extracted with ethyl acetate. The organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated to afford 6-Methoxy-1H-indole-2-carboxylic acid (4.60 g). This material (4.64 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (5.60 g) in dichloromethane (200 mL) were treated with N-methylpiperazine (3.23 mL) and stirred at ambient temperature for 16 h. The reaction mixture was poured into dichloromethane (200 mL), washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-10% 2M ammonia in methanol/dichloromethane) to give (6-Methoxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (6.60 g). This material (0.16 g) was dissolved in dichloromethane (10 mL). At room temperature, 1 M boron tribromide (1.5 mL) was added dropwise. The reaction mixture was heated to reflux overnight, and then cooled, quenched with saturated sodium hydrogencarbonate solution, and extracted with dichloromethane. The organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified via silica gel chromatography (0-10% 2M ammonia in methanol/dichloromethane) to give the title compound (0.12 g). ^1H NMR (400 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$): δ 7.22 (d, $J = 8.41 \text{ Hz}$, 1H), 6.62 (d, $J = 2.15 \text{ Hz}$, 1H), 6.5-6.47 (m, 2H), 3.69 (br s, 4H), 2.30 (t, $J = 5.09 \text{ Hz}$, 4H), 2.13 (s, 3H). MS

(electrospray): exact mass calculated for $C_{14}H_{17}N_3O_2$, 259.13; m/z found, 260.1 [M+H]⁺.

5

EXAMPLE 64

 $K_i = 41$ nM

(5-Chloro-1H-indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone


10 A mixture of 5-chloroindole-2-carboxylic acid (0.196 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.288 g) in dichloromethane (10 mL) was treated with 2-Methyl-piperazine (0.15 g) and stirred at ambient temperature for 16 h. The reaction mixture was poured into dichloromethane (50 mL), washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-10% methanol/dichloromethane) to give the title compound (0.229 g). ¹H NMR (400 MHz, CDCl₃): δ 10.99 (br s, 1H), 7.55 (d, J = 1.76 Hz, 1H), 7.33 (d, J = 8.80 Hz, 1H), 7.14 (dd, J = 1.96, 6.65 Hz, 1H), 6.63 (br s, 1H), 4.55 (br s, 2H), 3.23-2.61 (m, 5H), 1.76 (br s, 1H), 1.08 (d, J = 5.87 Hz, 1H). MS (electrospray): exact mass calculated for $C_{14}H_{16}ClN_3O$, 277.10; m/z found, 278.1 [M+H]⁺.

15

20

25

EXAMPLE 65


 $K_i = 36$ nM

(5-Chloro-1H-indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 10.99 (br s, 1H), 7.55 (d, J = 1.76 Hz, 1H), 7.33 (d, J = 8.80 Hz, 1H), 7.14 (dd, J = 1.96, 6.65 Hz, 1H), 6.63 (br s, 1H), 4.55 (br s, 2H), 3.23-2.61 (m, 5H), 1.76 (br s, 1H), 1.08 (d, J = 5.87 Hz, 1H). MS 5 (electrospray): exact mass calculated for C₁₄H₁₆ClN₃O, 277.10; m/z found, 278.1 [M+H]⁺.

EXAMPLE 66

10


 K_i = 34 nM

(5-Chloro-1H-indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone

¹H NMR (400 MHz, CDCl₃): δ 10.99 (br s, 1H), 7.55 (d, J = 1.76 Hz, 1H), 7.33 15 (d, J = 8.80 Hz, 1H), 7.14 (dd, J = 1.96, 6.65 Hz, 1H), 6.63 (br s, 1H), 4.55 (br s, 2H), 3.23-2.61 (m, 5H), 1.76 (br s, 1H), 1.08 (d, J = 5.87 Hz, 1H). MS (electrospray): exact mass calculated for C₁₄H₁₆ClN₃O, 277.10; m/z found, 278.1 [M+H]⁺.

20

EXAMPLE 67

 K_i = 27 nM

(5-Chloro-1H-indol-2-yl)-(3,4-dimethyl-piperazin-1-yl)-methanone

25


The product of Example 64, (5-Chloro-1H-indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone (0.19 g) was dissolved in dichloromethane (10 mL). At room temperature, paraformaldehyde (0.031g) was added, followed by acetic acid

(1drop). The reaction mixture was stirred at ambient temperature for 5 h. Sodium triacetoxyborohydride (0.318g) was added. The reaction mixture was stirred at ambient temperature for 16 h and poured into dichloromethane (20 mL), washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-10% methanol/dichloromethane) to give the title compound (0.22 g). ^1H NMR (400 MHz, CDCl_3): δ 10.69 (br s, 1H), 7.56 (d, J = 1.76 Hz, 1H), 7.33 (d, J = 8.80 Hz, 1H), 7.16 (dd, J = 1.96, 6.66 (d, J = 1.57 Hz, 1H), 4.63-4.36 (m, 2H), 3.63-2.67 (m, 3H), 2.30 (s, 3H), 2.30-2.20 (m, 1H), 2.18-2.09 (m, 1H), 1.12 (d, J = 5.87 Hz, 1H). MS (electrospray): exact mass calculated for $\text{C}_{15}\text{H}_{18}\text{ClN}_3\text{O}$, 291.11; m/z found, 292.1 $[\text{M}+\text{H}]^+$.

The title compound of the following example (68) was prepared according to the general procedure of Scheme 5.

EXAMPLE 68

K_i = 43 nM



(7-Amino-1H-indol-2-yl)-piperazin-1-yl-methanone


A mixture of 7-nitroindole-2-carboxylic acid (4.38 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.89 g) in dichloromethane (50 mL) was treated with piperazine-1-carboxylic acid tert-butyl ester (1.63 g) and stirred at ambient temperature for 16 h. The reaction mixture was poured into dichloromethane (20 mL), washed with water, saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-5% methanol/dichloromethane) to give 4-(7-Nitro-1H-indole-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester (2.17 g). This material (1.69 g) was dissolved

in CH_3OH (50 mL). At room temperature, ammonium formate (2.85 g) was added, followed by 10% palladium on carbon (0.47 g). The reaction mixture was heated to reflux for forty min, cooled and filtered through celite pad. The filtrate was concentrated and the residue was purified via silica gel chromatography (0-10% methanol/dichloromethane) to give 4-(7-Amino-1H-indole-2-carbonyl)-piperazine-1-carboxylic acid tert-butyl ester (1.34 g). This material (1.3 g) was treated with 20% trifluoroacetic acid/dichloromethane (50 mL) and stirred at ambient temperature for 1 h. The solvent was removed under reduced pressure to afford (7-Amino-1H-indol-2-yl)-piperazin-1-yl-methanone trifluoroacetate salt. This intermediate was dissolved in dichloromethane (100 mL), washed with saturated sodium hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-10% 2M ammonia in methanol/dichloromethane) to give the title compound (0.824 g). ^1H NMR (400 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$): δ 7.09 (d, J = 7.83 Hz, 1H), 6.95 (t, J = 7.63 Hz, 1H), 6.72 (s, 1H), 6.60 (d, J = 7.63 Hz, 1H), 4.20 (br s, 4H), 3.88 (br s, 4H), 2.94 (t, J = 5.09 Hz, 3H). MS (electrospray): exact mass calculated for $\text{C}_{13}\text{H}_{16}\text{N}_4\text{O}$, 244.13; m/z found, 245.1 $[\text{M}+\text{H}]^+$.

20 The title compounds of the following examples (69-70) were prepared according to the general procedure of Scheme 4.

EXAMPLE 69

25

 $K_i = 47 \text{ nM}$ 

(7-Hydroxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone


At room temperature, diethyl oxalate (13.6 mL) was added to a solution of 30 potassium ethoxide (8.4 g) in anhydrous ethyl ether (200 mL). After 10 min, 3-

methyl-2-nitroanisole (16.7 g) was added and stirred at ambient temperature for 24 h. The lumpy, deep purple potassium salt was separated by filtration and washed with anhydrous ether until the filtrate remained colorless. This salt was dissolved in aqueous ammonium chloride, and the solution was extracted 5 with dichloromethane. The combined organic extracts were washed with brine, dried over sodium sulfate and filtered, and the solvent was evaporated. The residue was purified via silica gel chromatography (5-30% ethyl acetate/hexanes) to give 3-(3-Methoxy-2-nitro-phenyl)-2-oxo-propionic acid ethyl ester (14.0 g). This material (14.0 g) was dissolved in ethanol (200 mL) 10 containing 5 wt. % palladium on activated carbon (1.4 g) and placed on a Parr hydrogenator at 60 psi H₂. After 2 h, the mixture was filtered through Celite, and concentrated to give a clear liquid. The liquid was purified by silica gel chromatography (5%-30% EtOAc/Hexanes) to obtain (7-Methoxy-1H-indol-2-yl)-(4-methyl-6-Methoxy-1H-indole-2-carboxylic acid ethyl ester (11.7 g). This 15 ethyl ester (4.0 g) was treated with lithium hydroxide (1.75 g) in THF (100 mL) followed by water (30 mL) and stirred at ambient temperature for 16 h. The solution was acidified with 10% hydrochloric acid, diluted with water and extracted with ethyl acetate. The organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated to afford 6-Methoxy-1H- 20 indole-2-carboxylic acid (3.50 g). This material (3.50 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (5.26 g) in dichloromethane (100 mL) were treated with N-methylpiperazine (3.05 mL) and stirred at ambient temperature for 16 h. The reaction mixture was poured into dichloromethane (200 mL), washed with water, saturated sodium 25 hydrogencarbonate solution and then brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0-10% methanol/dichloromethane) to give (7-Methoxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (4.50 g). This material (3.5 g) was dissolved in dichloromethane (85 mL). At room temperature, 1 M Boron 30 tribromide (2.42 mL) was added dropwise. The reaction mixture was heated to reflux for 2 h, cooled, and then quenched with saturated sodium hydrogencarbonate solution. The suspension was filtered. The filtrate was washed with saturated sodium hydrogencarbonate solution and then brine,

dried over sodium sulfate and filtered, and solvent was evaporated. The residue was purified via silica gel chromatography (0-10% methanol/dichloromethane) to give the title compound (1.95 g). ^1H NMR (400 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$): δ 7.52 (s, 1H), 7.16 (dd, $J = 0.78, 7.24$ Hz, 1H), 6.96 (t, $J = 7.63$ Hz, 1H), 6.77 (s, 1H), 6.70 (dd, $J = 0.98, 6.65$ Hz, 1H), 3.93 (br s, 4H), 2.55 (t, $J = 5.09$ Hz, 4H), 2.38 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{14}\text{H}_{17}\text{N}_3\text{O}_2$, 259.13; m/z found, 260.1 $[\text{M}+\text{H}]^+$.

10

EXAMPLE 70

 $K_i = 30$ nM


(5,7-Dimethyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

15

^1H NMR (400 MHz, CDCl_3): δ 10.68 (br s, 1H), 7.20 (s, 1H), 6.80 (s, 1H), 6.65 (d, $J = 2.15$ Hz, 1H), 3.91 (br s, 4H), 2.39 (t, $J = 4.50$ Hz, 4H), 2.35 (s, 6H), 2.26 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{16}\text{H}_{21}\text{N}_3\text{O}$, 271.17; m/z found, 272.1 $[\text{M}+\text{H}]^+$.

20

EXAMPLE 71

 $K_i = 19$ nM


(5-Hydroxy-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

25

A mixture of the product of Example 5, (5-Benzyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (0.2 g) in a mixture of ethanol (3 mL) and

ethylacetate (5 mL) was treated with 10% palladium on carbon (approximately 0.025 g) and hydrogenated at atmospheric pressure for 2 h. The reaction mixture was filtered through a pad of Celite and the residue washed with methanol. The solvent in the combined filtrates was removed under reduced pressure, and the residue was purified via silica gel chromatography (3-10% 5 2M ammonia in methanol/dichloromethane) to afford the title compound (0.034 g, 23%). ^1H NMR (400 MHz, CD_3OD): δ 7.20 (d, J = 8.0 Hz, 1H), 6.90 (m, 1H), 6.75 (dd, J = 4, 8 Hz, 1H), 6.54 (m, 1H), 3.80 (br.m, 4H), 2.44 (m, 4H), 2.27 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{14}\text{H}_{17}\text{N}_3\text{O}_2$, 259.13; m/z 10 found, 260.0 $[\text{M}+\text{H}]^+$.

EXAMPLE 72

 $K_i = 11 \text{ nM}$ 

15

(4,5-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

The title compound was prepared according to the general procedure of Scheme 2. A mixture of 3,4-dichlorophenylhydrazine (5.0 g) in benzene (50 mL) was treated sequentially with ethylpyruvate (2.6 mL) and p-toluenesulfonic acid (trace). The mixture was heated at reflux temperature (Dean and Stark conditions) for 5 h then cooled to ambient temperature to afford a solution of 2-[(3,4-dichloro-phenyl)-hydrazone]-propionic acid ethyl ester. Separately a solution of p-toluenesulfonic acid (15 g) in benzene (150 mL) was heated at 20 reflux temperature (Dean and Stark conditions) for 2 h and then treated with the hydrazone solution. After 3 h the reaction mixture was cooled, treated with saturated sodium hydrogen carbonate solution and diethyl ether. The organic fraction was separated, washed with saturated sodium hydrogen carbonate solution and then brine, dried over magnesium sulfate and filtered, and solvent 25

was evaporated to give an orange solid. The solid was purified via silica gel chromatography (15-75% ethylacetate/hexane) to afford 4,5-Dichloro-1H-indole-2-carboxylic acid ethyl ester (0.5 g, 8%) and 5,6-Dichloro-1H-indole-2-carboxylic acid ethyl ester (0.297 g, 5%). These materials were used

5 separately without further purification.

4,5-Dichloro-1H-indole-2-carboxylic acid ethyl ester (0.5 g) was treated with 1M lithium hydroxide in ethanol (3 mL) and heated, water bath, for 2 h. The solution was acidified with 10% hydrochloric acid, diluted with water and extracted with ethylacetate. The organic extracts were combined, dried over


10 sodium sulfate and filtered, and solvent was evaporated to give 4,5-dichloro-1H-indole-2-carboxylic acid (0.27 g, 60%). This material was treated with -ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride (0.5 g), HOBT (0.4 g) and N, N-diisopropylethylamine (1 mL) in DMF (2 mL) and dichloromethane (2 mL) was treated with N-methylpiperazine (0.2 mL) stirred at ambient

15 temperature for 18 h then diluted with water. The organic portion was separated, washed with brine, dried over sodium sulfate, and filtered. Solvent was removed under reduced pressure, and the residue was purified via silica gel chromatography (3-8% 2M ammonia in methanol/dichloromethane) to give the title compound (0.15 g, 40%). ^1H NMR (400 MHz, CDCl_3): δ 10.2 (br.s, 1H), 7.25 – 7.16 (m, 2H), 6.75 (d, J = 2 Hz, 1H), 3.92 (br.m, 4H), 2.47 (m, 4H), 2.30 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{14}\text{H}_{15}\text{Cl}_2\text{N}_3\text{O}$, 311.06; m/z found, 312.0 $[\text{M}+\text{H}]^+$.

20

25

EXAMPLE 73

 K_i = 259 nM


(5,6-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone

Using the procedure of the previous example (72), the title compound was prepared from 5,6-Dichloro-1H-indole-2-carboxylic acid ethyl ester. ^1H NMR (400 MHz, CDCl_3): δ 9.9 (br.s, 1H), 7.97 (s, 1H), 7.79 (m, 1H), 6.94 (m, 1H), 4.20 (br.m, 4H), 2.77 (m, 4H), 2.26 (s, 3H). MS (electrospray): exact mass 5 calculated for $\text{C}_{14}\text{H}_{15}\text{Cl}_2\text{N}_3\text{O}$, 311.06; m/z found, 312.0 $[\text{M}+\text{H}]^+$.

The title compound of the following example (74) was prepared according to the general procedure of Scheme 5.

10

EXAMPLE 74

 $K_i = 0.025 \mu\text{M}$ 

(5-Chloro-1H-indol-2-yl)-[4-(2-hydroxyethyl)-piperazin-1-yl]-methanone

15 A. 4-(5-Chloro-1H-indole-2-carbonyl)-piperazine-1-carboxylic acid *tert*-butyl ester.

A mixture of 5-chloroindole-2-carboxylic acid (10 g), *tert*-butyl 1-piperazinecarboxylate (10.5 g) and 4-dimethylaminopyridine (6.3 g) in CH_2Cl_2 (200 mL) was treated with a catalytic amount of HOBT (0.2 g). The resulting 20 mixture was cooled to 0 °C, and EDCI (10.8 g) was added. The reaction was then slowly warmed to ambient temperature and stirred for 24 h then concentrated under reduced pressure. Water was added to the resulting residue. The product precipitated and was washed with water (2 x 50 mL) and Et_2O (30 mL). The resulting solid was dried under reduced pressure to yield 25 (18.2 g). MS (electrospray): exact mass calculated for $\text{C}_{18}\text{H}_{22}\text{ClN}_3\text{O}_3$, 363.13; m/z found, 362.3 $[\text{M}-\text{H}]^+$.

B. (5-Chloro-1H-indol-2-yl)-piperazin-1-yl-methanone.

The product from Step A (11 g) was suspended in CH_2Cl_2 (75 mL), and TFA was added dropwise (75 mL). The resulting solution was stirred overnight at ambient temperature. The reaction solution was concentrated under reduced pressure, and the resulting residue was dissolved in CH_2Cl_2 (100 mL).

5 Saturated aqueous NaHCO_3 (100 mL) was added slowly with stirring. After 20 min the organic layer was separated, washed with water (10 mL) and then brine (30 mL), and dried over Na_2SO_4 . The organic layer was then concentrated under reduced pressure and purified via silica gel chromatography (0-35% methanol/dichloromethane) to give the title compound

10 (7.6 g). MS (electrospray): exact mass calculated for $\text{C}_{13}\text{H}_{14}\text{ClN}_3\text{O}$, 263.08; m/z found, 264.1 $[\text{M}+\text{H}]^+$.

C. (5-Chloro-1H-indol-2-yl)-[4-(2-hydroxy-ethyl) -piperazin-1-yl]-methanone.

The product from Step B (1.0 g) was dissolved in CH_3CN (10 mL) and treated


15 with 2-bromoethanol (0.5 g) and then K_2CO_3 (0.8 g). The resulting mixture was heated at 60 °C overnight. The mixture was cooled to ambient temperature, filtered, and concentrated under reduced pressure. The resulting residue was purified via silica gel chromatography (0-10% methanol/dichloromethane) to give the title compound (0.5 g). ^1H NMR (400 MHz, CDCl_3): δ 10.09 (br s, 1H),

20 7.61 (d, J = 2.0 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 7.23 (dd, J = 2.0, 8.8 Hz, 1H), 6.69 (d, J = 0.8 Hz, 1H), 3.95 (br m, 3H), 3.72-3.69 (m, 2H), 2.67-2.64 (m, 4H), 2.52 (br s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{15}\text{H}_{18}\text{ClN}_3\text{O}_2$, 307.78; m/z found, 308.1 $[\text{M}+\text{H}]^+$.

25

EXAMPLE 75

$K_i = 0.145 \mu\text{M}$



[5-(3-Methoxy-phenyl)-1H-indol-2-yl]-[4-(4-methyl-piperazin-1-yl)-methanone]


A suspension of (5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone (Example 3, 0.057 g) in dry toluene (0.5 mL) was treated with $\text{Pd}(\text{OH})_2$ (0.001 g) under N_2 atmosphere. The resulting mixture was then treated with 3-methoxyphenylboronic acid (0.057 g) and then K_3PO_4 (0.12 g), and heated at 95 °C for 24 h. The reaction mixture was cooled to ambient temperature and diluted with water (2 mL) and toluene (10 mL). The organic layer was separated and washed with brine (2 mL), dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The resulting residue was purified via 10 silica gel chromatography (0-12% methanol/dichloromethane) to give the title compound (0.005 g). ^1H NMR (400 MHz, CDCl_3): δ 9.96 (br s, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.51 (d, J = 1.6 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.23 (s, 1H), 7.21 (s, 1H), 7.17 (m, 1H), 6.87 (dd, J = 2.2, 8.1 Hz, 1H), 6.82 (d, J = 1.8 Hz, 1H), 3.99 (br s, 4H), 3.86 (s, 3H), 2.52 (t, J = 4.9 Hz, 4H), 2.35 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{21}\text{H}_{23}\text{N}_3\text{O}_2$, 349.18; m/z found, 350.2 15 $[\text{M}+\text{H}]^+$.

The title compound of the following example (76) was prepared according to the general procedure of Example 75.

20

EXAMPLE 76

$K_i = 0.327 \mu\text{M}$



(4-Methyl-piperazin-1-yl)-(5-p-tolyl-1H-indol-2-yl)-methanone

25

^1H NMR (400 MHz, CDCl_3): δ 9.24 (br s, 1H), 7.81 (m, 1H), 7.54-7.46 (m, 5 H), 7.26 (d, J = 7.8 Hz, 1H), 6.82 (dd, J = 0.7, 2.1 Hz, 1H), 3.97 (br s, 4H), 2.52 (t, J = 5.1, 4H) 2.40 (s, 3H), 2.36 (s, 3H). MS (electrospray): exact mass calculated for $\text{C}_{21}\text{H}_{23}\text{N}_3\text{O}$, 333.18; m/z found, 334.2 $[\text{M}+\text{H}]^+$.

F. Biological Examples

EXAMPLE 1

5

Binding assay on recombinant human histamine H₄ receptor

SK-N-MC cells or COS7 cells were transiently transfected with pH4R and grown in 150 cm² tissue culture dishes. Cells were washed with saline solution, scraped with a cell scraper and collected by centrifugation (1000 rpm, 10 min). Cell membranes were prepared by homogenization of the cell pellet in 20 mM Tris-HCl with a polytron tissue homogenizer for 10 s at high speed. Homogenate was centrifuged at 1000 rpm for 5 min at 4 °C. The supernatant was then collected and centrifuged at 20,000 x g for 25 min at 4 °C. The final pellet was resuspended in 50 mM Tris-HCl. Cell membranes were incubated 15 with ³H-histamine (5 nM - 70 nM) in the presence or absence of excess histamine (10000 nM). Incubation occurred at room temperature for 45 min. Membranes were harvested by rapid filtration over Whatman GF/C filters and washed 4 times with ice cold 50 mM Tris HCl. Filters were then dried, mixed with scintillant and counted for radioactivity. SK-N-MC or COS7 cells 20 expressing human histamine H₄ receptor were used to measure the affinity of binding of other compounds and their ability to displace ³H-ligand binding by incubating the above described reaction in the presence of various concentrations of inhibitor or compound to be tested. For competition binding studies using ³H-histamine, K_i values were calculated based on an 25 experimentally determined K_D value of 5 nM and a ligand concentration of 5 nM according to Cheng and Prusoff where; K_i = (IC₅₀)/(1 + ([L]/(K_D))).

EXAMPLE 2

The inhibition of zymosan induced peritonitis in mice by histamine H4 receptor30 antagonists

This example demonstrates the discovery that histamine H₄ receptor antagonists can block the peritonitis induced by zymosan, which is the insoluble polysaccharide component on the cell wall of *Saccharomyces cerevisiae*. This is commonly used to induce peritonitis in mice and appears to

5 act in a mast cell dependent manner.

Materials and Methods.

Animals

10 Male out-bred Swiss albino mice were purchased from Bantin and Kingman (T.O. strain; Hull, Humberside) and maintained on a standard chow pellet diet with tap water *ad libitum* and a 12:00 h light /dark cycle. All animals were housed for at least 3 days prior to experimentation to allow body weight to reach ~30 g on the day of the experiment. For this particular experiment body

15 weight was 30.5 ± 0.3 g (n = 32). Animals were briefly (30–60 s) anesthetized with halothane for all s.c. and i.p. treatments described below.

Drug treatment and Experimental Design

20 Drugs were stored at room temperature, in the dark. On the day of the experiment, drugs were dissolved in sterile PBS as depicted below, and generously vortexed.

25 The compound from Chemical Example 1 was prepared at 10 mg/5mL, and injected at 5 mL/kg. Imetit was prepared at 5 mg/5 mL, and injected at 5 mL/kg.

Thioperamide was prepared at 5 mg/5 mL, and injected at 5 mL/kg.

Time -15 min: Compounds or PBS administered s.c. at the reported doses.

30 Time 0: At time 0, mice received 1 mg zymosan A (Sigma) i.p.

Time +2h: Compounds or PBS administered s.c. at the reported doses.

Time +4: Peritoneal cavities were washed 4 h later with 3 mL of PBS containing 3 mM EDTA, and the number of migrated leukocytes determined, by

taking an aliquot (100 μ L) of the lavage fluid and diluting 1:10 in Turk's solution (0.01% crystal violet in 3% acetic acid). The samples were then vortexed and 10 μ L of the stained cell solution were placed in a Neubauer haemocytometer. Differential cell counts were performed using a light microscope (Olympus 5 B061). In view of their chromatic characteristics and their nucleus and cytoplasm appearance, polymorphonuclear leukocytes (PMN; >95% neutrophils) could be easily identified.

Experimental groups are described below:

10 PBS + zymosan, n = 8
 Compound from Example 1 + zymosan, n = 8
 Imetit + zymosan, n = 8
 Thioperamide + zymosan, n = 8

Statistics

15 Data are shown for single mice, and also shown as mean \pm SD or Standard Error (SE) of 8 mice per group. The % of inhibition is also shown. Statistical differences were determined by Anova followed by Bonferroni's post-hoc test.

20 Results

Table 1. Effect of compounds on zymosan peritonitis

Treatment	n	PMN (10^6 per mouse)	mean	SD	SE	P value
						(% inhib)
PBS	1	15.9	17.2	2.4	0.8	
(s.c.)	2	18.3				
	3	16.2				
	4	17.4				
	5	19.8				
	6	12.6				
	7	19.8				

	8	17.7					
Compound 1 (10mg/kg; s.c.)	1	9.9	6.6	2.7	1.0	0.001	
	2	3.6					(-62%)
	3	9.3					
	4	3.3					
	5	8.1					
	6	5.1					
	7	6.9					
Imetit (5mg/kg; s.c.)	1	19.8	17.3	2.6	0.9	n.s.	
	2	17.1					
	3	14.1					
	4	15.3					
	5	21.3					
	6	17.7					
	7	14.1					
	8	18.6					
Thioperamide (5mg/kg; s.c.)	1	9.3	9.3	3.4	1.2	0.001	
	2	16.5					(-46%)
	3	7.2					
	4	10.8					
	5	5.4					
	6	9.9					
	7	6.9					
	8	8.1					

From data analysis it can be seen that zymosan produced a leukocyte extravasation response that was intense at the 4 h time-point. Treatment with 10 mg/kg Compound 1 significantly reduced PMN influx (compare PBS group 5 to Compound 1 group in Table1). The degree of inhibition was >60%. Imetit (5 mg/kg) was inactive, whereas a significant inhibitory effect was attained by 5 mg/kg thioperamide.

Conclusion

To conclude, this study demonstrates that a histamine H₄ receptor antagonist, Compound 1, given at the dose of 10 mg/kg, is effective in reducing PMN accumulation in an experimental model of cell recruitment in response to local application of zymosan in the mouse peritoneal cavity. Furthermore thioperamide which is a dual H₃/H₄ receptor antagonist is also effective. The dual H₃/H₄ receptor agonist, Imetit, does not have any effect. This shows that an antagonist of the histamine H₄ receptor can block inflammation induced by zymosan.

EXAMPLE 3

The inhibition of sodium urate crystal induced peritonitis in mice by histamine H₄ receptor antagonists

This example demonstrates the discovery for the first time that histamine H₄ receptor antagonists can block the peritonitis induced by sodium urate crystals. Such crystals are the primary cause of the inflammation associated with acute gouty arthritis.

Materials and Methods.

Animals

Male out-bred Swiss albino mice were purchased from Bantin and Kingman (T.O. strain; Hull, Humberside) and maintained on a standard chow pellet diet with tap water *ad libitum* and a 12:00 h light /dark cycle. All animals were housed for at least 3 days prior to experimentation to allow body weight to reach ~30 g on the day of the experiment. For this particular experiment body weight was 30 ± 1 (n=32).

Drug treatment and Experimental Design

Compound 1 was stored at room temperature in the dark. On the day of the experiment, Compound 1 was dissolved in phosphate buffered saline (PBS) to a concentration of 3 mg/mL. At *time -15 min* Compound 1 was administered s.c. at the dose of 10 mg/kg, whereas the control group received the vehicle 5 alone (10 mL/kg). Mice received 3 mg mono sodium urate crystals (MSU) given intra-peritoneally at *time 0*. At *time +2h* and *time +4h*, Compound 1 (10 mg/kg) or vehicle (10 mL/kg) were given s.c.

Time +6 h: Peritoneal cavities were washed 6 h later with 3 mL of PBS 10 containing 3 mM EDTA, and the number of migrated leukocytes determined, by taking an aliquot (100 μ L) of the lavage fluid and diluting 1:10 in Turk's solution (0.01% crystal violet in 3% acetic acid). The samples were then vortexed and 10 μ L of the stained cell solution were placed in a Neubauer hematocytometer. Differential cell counts were performed using a light microscope (Olympus 15 B061). In view of their chromatic characteristics and their nucleus and cytoplasm appearance, cells polymorphonuclear cells (PMN, >95% neutrophils) could be easily differentiated.

Experimental groups are described below:
20

Vehicle + MSU crystals n=8
Compound 1 + MSU crystals n=8

Statistics

Data are shown for single mice, and also shown as mean \pm SE of (n) mice per 25 group. Statistical differences were determined by Student's *t* test. A P value <0.05 was taken as significant.

Results

30 Table 2. Effect of Compound 1 on MSU-induced leukocyte migration as evaluated at the 6 h time-point.

Treatment	n	PMN (10 ⁸ per mouse)	mean	SD	SE	P value
						(% inhib)
PBS (s.c.)	1	9.6	8.9	2.2	0.8	
	2	12.9				
	3	7.2				
	4	9.9				
	5	6.6				
	6	7.2				
	7	10.5				
	8	7.5				
Compound 1 (10mg/kg; s.c.)	1	7.8	6.8	2.1	0.7	0.04
	2	4.5				(-24%)
	3	3.0				
	4	7.8				
	5	8.1				
	6	9.3				
	7	6.6				
	8	7.2				

Mice were treated with either PBS (10 mL/kg) or Compound 1 (10 mg/kg) at -15 min, +2 h and +4 h, and with 3 mg MSU crystals at time 0. PMN influx into the peritoneal cavity was measured at the 6 h time-point after collection of the lavage fluids and specific staining as described in the experimental section.

Conclusion

10 As expected, MSU crystals produced a PMN extravasation that was intense at the 6 h time-point. Treatment with a specific histamine H₄ receptor antagonist, Compound 1, significantly reduced PMN migration (Table 2): the degree of inhibition was 24%. To conclude, this study demonstrates that a histamine H₄ receptor antagonist is effective in reducing PMN accumulation in an

experimental model of cell recruitment in response to local application of MSU crystals in the mouse peritoneal cavity.

5

EXAMPLE 4

The inhibition of croton oil induced topical inflammation in mice by histamine H₄ receptor antagonists

10 This example demonstrates the discovery that histamine H₄ receptor antagonists can block the inflammation associated with topical application of croton oil.

Materials and Methods.

15 Animals

Male or female ICR derived mice weighing 22 ± 1 g were used. Space allocation for 5 animals was 45 x 23 x 15 cm. Mice were housed in APEC R cages. All animals were maintained in a controlled temperature (22 °C - 24 °C) and humidity (60% - 80%) environment with 12 h light/dark cycles. Free access 20 to standard lab chow for Mice (LabDiet Rodent Diet, PMI Nutrition International, USA) and tap water was granted.

Chemicals

25 Acetone (Wako, Japan), Croton oil (Sigma, USA), Indomethacin (Sigma, USA) and Pyrogen free saline (Astar, Taiwan).

Protocol Croton Oil Induced Topical Inflammation

Groups of 5 ICR derived male mice weighing 22 ± 1 g were used. Compound 1 (10 mg/kg) and vehicle (0.9% NaCl) as well as the positive control 30 Indomethacin (30 mg/kg) were administered subcutaneously to test animals at 30 min before, and 2 and 4 h after croton oil (8% in 20 µL acetone) was applied topically. Ear swelling was measured by Dyer model micrometer gauge 6 h after croton oil as an index of inflammation.

Results

Table 3. Effect of Compound 1 on Croton Oil Induced Topical Inflammation

5

Treatment	n	Difference in ear		P value	
		Thickness (x0.01 mm)	Mean	SE	(% inhib)
PBS	1	12	16.6	1.4	
(s.c.)	2	17			
	3	15			
	4	19			
	5	20			
Compound 1 (10mg/kg; s.c.)	1	12	12.0	1.2	0.03
	2	10			(-28%)
	3	13			
	4	9			
	5	16			
Indomethacin (30mg/kg; s.c.)	1	5	10.0	1.3	0.001
	2	10			(-40%)
	3	12			
	4	12			
	5	11			

Conclusions

In the croton oil induced topical inflammation ear swelling assay, a histamine H₄ receptor antagonist, Compound 1, at a dose of 10 mg/kg x 3 (s.c.) significantly reduced the swelling with respect to the vehicle control. This effect was similar to Indomethacin (30 mg/kg x 3). These results show that a histamine H₄ receptor antagonist can act as an anti-inflammatory agent.

15

EXAMPLE 5

Cell-type Distribution of H₄ Expression

RNA was prepared from the different cells using a RNeasy kit (Qiagen, 5 Valencia, CA) according to the manufacturer's instructions. RNA samples (5 µg) were run on an RNA gel and then transferred overnight to a nylon blot (Hybond, Amersham Pharmacia Biotech, Piscataway, NJ). The blot was pre-hybridized with ExpressHyb solution (CLONTECH) for 30 min at 68 °C. The H₄ receptor DNA was labeled using the rediprime II kit (Amersham Pharmacia 10 Biotech). The blot was hybridized for 2 h at 68 °C, followed by one wash step (0.23 SSC and 0.05% SDS) of 40 min at room temperature, and a second wash step (0.13 SSC and 0.1% SDS) of 40 min at 50 °C. The blot was exposed to X-ray film at 27 °C with two intensifying screens overnight.

15 Conclusion

The Northern Blot results indicate that the H₄ receptor is expressed on bone-marrow derived mast cells (BMMC) peritoneal mast cells, and eosinophils. These positive results are consistent with the published literature (eg. Oda et al., Nguyen et al., and Morse et al. in the Background section). 20 However, the negative results of the Northern Blot experiment, such as the finding of apparently no measurable levels of H₄ receptor expressed by neutrophils, differ somewhat from the above literature findings. This may be explained by the different methodologies used. Additional investigation may also clarify these issues.

Table 4. Cell-type Distribution of H₄ Expression by Northern Blot

Species	Cell Type	H ₄
Human	Eosinophils	+
	Immature Dendritic Cells	-
	Mature Dendritic Cells	-
	CD14 ⁺ Monocytes	-
	CD4 ⁺ T Cells	-
	CD8 ⁺ T Cells	-
	B Cells	-
	Neutrophils	-
Mouse	Eosinophils	+
	Peritoneal Mast Cells	+
	BMMC	+
	BM Derived Macrophages	-
	Peritoneal Macrophages	-
	CD4 ⁺ T Cells	-
	B Cells	-

5 G. Other Embodiments

The features and advantages of the invention are apparent to one of ordinary skill in the art. Based on this disclosure, including the summary, detailed description, background, examples, and claims, one of ordinary skill in the art will be able to make modifications and adaptations to various conditions and usages. Publications described herein are incorporated by reference in their entirety. These other embodiments are also within the scope of the invention.

What is claimed is:


Claims

1. A compound of formula (I) wherein:

5

10

15



Wherein R_1 is R_a , R_aR_b , R_a-O-R_b , or $(R_c)(R_d)N-R_b$, where R_a is H, cyano, $-(C=O)N(R_c)(R_d)$, $-C(=NH)(NH_2)$, C_{1-10} alkyl, C_{3-8} alkenyl, C_{3-8} cycloalkyl, C_{2-5} heterocyclic radical, or phenyl; where R_b is C_{1-8} alkylene, C_{2-8} alkenylene, C_{3-8} cycloalkylene, bivalent C_{3-8} heterocyclic radical, or phenylene, and R_c and R_d are each independently H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{3-8} cycloalkyl, or phenyl;

R_2 is H, methyl, ethyl, NR_pR_q , $-(CO)NR_pR_q$, $-(CO)OR_r$, $-CH_2NR_pR_q$, or CH_2OR_r ; where R_p , R_q , and R_r are independently selected from C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl; $(C_{3-6}$ cycloalkyl) $(C_{1-2}$ alkylene), benzyl or phenethyl; or R_p and R_q taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, and N;

R_3 is H, methyl, ethyl, NR_sR_t , $-(CO)NR_sR_t$, $-(CO)OR_u$, $-CH_2NR_sR_t$, or CH_2OR_u ; where R_s , R_t , and R_u are independently selected from C_{1-6} alkyl, C_{3-8} cycloalkyl, phenyl; $(C_{3-6}$ cycloalkyl) $(C_{1-2}$ alkylene), benzyl or phenethyl; or R_s and R_t taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, and N;


R_5 is methyl, ethyl, or H;

R_6 is methyl, ethyl, or H;
 R_7 is methyl, ethyl, or H;
 X_4 is NR₁ or S;
 X_1 is CR₃;
5 R_3 is F, Cl, Br, CHO, R_f, R_fR_g-, R_fO-R_g-, or (R_h)(R_i)N-R_g-, where R_f is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, C₂₋₅ heterocyclic radical, or phenyl; where R_g is C₁₋₆ alkylene, C₂₋₆ alkenylene, C₃₋₆ cycloalkylene, bivalent C₃₋₆ heterocyclic radical, or phenylene; and R_h and R_i are each independently H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl, or phenyl;
10 X_2 is NR_e or O, provided that X₂ is NR_e where X₁ is N; R_e is H or C₁₋₆ alkyl;
 X_3 is N;
 Z is =O or =S;
 each of R₄ and R₆ is independently H, F, Cl, Br, I, COOH, OH, nitro,
15 amino, cyano, C₁₋₄ alkoxy, or C₁₋₄ alkyl;
 R₅ is H, F, Cl, Br, I, (C=O)R_j, OH, nitro, NR_jR_k, cyano, phenyl, -OCH₂-Ph, C₁₋₄ alkoxy, or C₁₋₄ alkyl;
 R₇ is H, F, Cl, Br, I, (C=O)R_m, OH, nitro, NR_lR_m, cyano, phenyl, -OCH₂-Ph C₁₋₄ alkoxy, or C₁₋₄ alkyl;
20 wherein each of R₁, R_k, R_l, and R_m is independently selected from H, C₁₋₆ alkyl, hydroxy, phenyl, benzyl, phenethyl, and C₁₋₆ alkoxy;
 each of the above hydrocarbyl (including alkyl, alkoxy, phenyl, benzyl, cycloalkyl, and so on) or heterocyclic groups being independently and optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, halo, hydroxy, amino, and C₁₋₃ alkoxy;
25 wherein n is 0, 1, or 2; where n is 2, the moiety -(CHR₅)_{n=2}- is -(CHR₅-CHR₇)- where CHR₅ is between CHR₆ and CHR₇;
 provided at least one of R₁, R₂, R₃, R₄, R₅, R₆, and R₇ is other than H when Z is O;
30 and provided, where Z is O, n =1, and each of R₄, R₅, R₆, R₇, R₂, R₃, R₅, and R₆ is H, then (a) where X₂ is NH, then R₁ is (i) not methyl, pyridyl, phenyl, or benzyl, and (b) where X₂ is O, then R₁ is not methyl;

and provided, where Z is O, X₂ is NH, n = 1, R₁ is methyl, each of R₄, R₆, R₇, R₂, R₃, R₅, and R_{6'} is H, then R₅ is not methoxy; or a pharmaceutically acceptable salt, ester, or amide thereof.

5

2. A compound of claim 1 of the following formula wherein:



Wherein R₁ is R_a, R_aR_b-, R_a-O-R_b-, or (R_c)(R_d)N-R_b-, where R_a is H, C₁₋₁₀ alkyl, C₃₋₈ alkenyl, C₃₋₈ cycloalkyl, C₂₋₅ heterocyclic radical, or phenyl;

10 where R_b is C₁₋₈ alkylene, C₃₋₈ alkenylene, C₃₋₈ cycloalkylene, bivalent C₃₋₈ heterocyclic radical, or phenylene; and R_c and R_d are each independently H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, or phenyl;

R₂ is ortho or meta, and is methyl or H;

X₁ is CR₃;

15 R₃ is F, Cl, Br, R_f, R_fR_g-, R_fO-R_g-, or (R_h)(R_i)N-R_g-, where R_f is H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₈ cycloalkyl, C₂₋₅ heterocyclic radical, or phenyl; where R_g is C₁₋₆ alkylene, C₂₋₆ alkenylene, C₃₋₆ cycloalkylene, bivalent C₃₋₆ heterocyclic radical, or phenylene; and R_h and R_i are each independently H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, or phenyl;

20 X₂ is NR_e or O, provided that X₂ is NR_e where X₁ is N; R_e is H or C₁₋₈ alkyl;

X₃ is N;

Z is =O or =S;

each of R₄ and R₆ is independently H, F, Cl, Br, I, COOH, OH,

25 nitro, amino, cyano, C₁₋₄ alkoxy, or C₁₋₄ alkyl;

R_5 is H, F, Cl, Br, I, $(C=O)R_j$, OH, nitro, NR_jR_k , cyano, $-OCH_2-Ph$, C_{1-4} alkoxy, or C_{1-4} alkyl;

R₇ is H, F, Cl, Br, I, (C=O)R_m, OH, nitro, NR₁R_m, cyano, C₁₋₄ alkoxy, or C₁₋₄ alkyl;

5 wherein each of R_j , R_k , R_l , and R_m is independently selected from H, C_{1-6} alkyl, hydroxy, phenyl, benzyl, phenethyl, and C_{1-6} alkoxy; each of the above hydrocarbyl or heterocyclic groups being independently and optionally substituted with between 1 and 3 substituents selected from C_{1-6} alkyl, halo, hydroxy, amino, and C_{1-6} alkoxy;

10 n is 1;
provided at least one of R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , and R_7 is other
than H when Z is O;
or a pharmaceutically acceptable salt, ester, or amide thereof.

15 4. A compound of claim 1, wherein
R₁ is H, methyl, or ethyl;
One of R₂ and R₃ is methyl, and the other is H, where R₁ is H; R₂
is otherwise H;

20 X_1 is CR₃; R₃ is H, F, Cl, or Br;
 X_2 is NR_e or O;
 R_e is H or C₁₋₃ alkyl;
 Z is =O or =S;
 each of R₄ and R₆ is independently H, OH, C₁₋₄ alkyl, C₁₋₄ alkoxy,
 cyano, or amino;

25 R_5 is H, F, Cl, Br, COOH, OH, amino, cyano, C_{1-4} alkoxy, or C_{1-4} alkyl; and

R_7 is H, F, Cl, Br, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, or amino; provided at least one of R_5 and R_7 is not H.

30 5. A compound of claim 1, wherein

R_1 is H, methyl, or ethyl;

R_2 and R_3 are independently methyl or H;

X_1 is CR₃ or N; R₃ is H, F, or Cl;

X_2 is NR_e or O, provided that X_2 is NR_e where X_1 is N; R_e is H or C₁₋₆ alkyl;

Z is =O or =S;

each of R_4 and R_6 is H;

5 R_5 is H, F, Cl, Br, methyl, ethyl, or propyl; and

R_7 is H, F, Cl, Br, or C_{1-4} alkyl; provided at least one of R_5 and R_7

is not H.

6. A compound of claim 1, wherein X_2 is N.
7. A compound of claim 1, wherein X_2 is O.
8. A compound of claim 1, wherein R_1 is H, methyl or ethyl.
9. A compound of claim 8, wherein R_1 is methyl.
10. A compound of claim 1, wherein R_2 is H.
11. A compound of claim 1, wherein R_2 is methyl.
12. A compound of claim 1, wherein R_3 is H or Cl.
13. A compound of claim 12, wherein R_3 is Cl.
14. A compound of claim 1, wherein R_5 is F, Cl, Br, or methyl and R_7 is F, Cl, or Br.
15. A compound of claim 1, wherein each of R_5 and R_7 is independently selected from H, F, Cl, Br, and methyl, provided at least one of R_5 and R_7 is not H.
16. A compound of claim 1, wherein each of R_4 and R_6 is independently H, methyl, or Cl.

17. A compound of claim 1, wherein R_3 is H or Cl; R_5 is F, Cl, Br, or methyl; and R_7 is H, F, Cl, or Br.
- 5 18. A compound of claim 17, wherein each of R_4 and R_6 is independently H, methyl, or Cl.
19. A compound of claim 1, wherein Z is =S.
- 10 20. A compound of claim 1 selected from: (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Fluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5,7-Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (7-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5,7-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (3,5-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone.
- 15
- 20 21. A compound of claim 1 selected from: (6-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (1H-Indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone; (7-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-benzofuran-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanethione.
- 25
22. A compound of claim 20 selected from: (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5,7-Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (5,7-Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone.
- 30

23. A compound of claim 1, selected from:
(4-Methyl-piperazin-1-yl)-(5-trifluoromethyl-1H-indol-2-yl)-
methanone; (7-Amino-5-methyl-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (5-Amino-7-methyl-1H-indol-2-yl)-(4-
5
methyl-piperazin-1-yl)-methanone; (7-Amino-5-bromo-1H-indol-2-
yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Amino-7-bromo-1H-
indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Fluoro-7-
methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (7-
10
Fluoro-5-methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-
methanone; (6-Bromo-5-hydroxy-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (5-Bromo-6-hydroxy-1H-indol-2-yl)-(4-
methyl-piperazin-1-yl)-methanone; (6-Bromo-7-hydroxy-1H-indol-
2-yl)-(4-methyl-piperazin-1-yl)-methanone; (4-Bromo-7-hydroxy-
15
1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (6-Bromo-7-
methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and
(4-Bromo-7-methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-
methanone.

24. A compound of claim 1, selected from: (5,7-Dichloro-1H-indol-2-
20
yl)-piperazin-1-yl-methanone; (5,7-Difluoro-1H-indol-2-yl)-
piperazin-1-yl-methanone; (5,7-Difluoro-1H-indol-2-yl)-(3-methyl-
piperazin-1-yl)-methanone; (5,6-Difluoro-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; and (4,6-Difluoro-1H-indol-2-yl)-(4-
methyl-piperazin-1-yl)-methanone.

25
25. A compound of claim 1, selected from:
1-(5-Chloro-1H-indole-2-carbonyl)-4-methyl-piperazine-2-
carboxylic acid methyl ester; 4-(5-Chloro-1H-indole-2-carbonyl)-1-
methyl-piperazine-2-carboxylic acid methyl ester; 4-(5-Chloro-1H-
30
indole-2-carbonyl)-1-methyl-piperazine-2-carboxylic acid amide;
1-(5-Chloro-1H-indole-2-carbonyl)-4-methyl-piperazine-2-
carboxylic acid amide; 4-(5-Chloro-1H-indole-2-carbonyl)-1-
methyl-piperazine-2-carboxylic acid methylamide; 1-(5-Chloro-1H-

indole-2-carbonyl)-4-methyl-piperazine-2-carboxylic acid
methylamide; 4-(5-Chloro-1H-indole-2-carbonyl)-1-methyl-
piperazine-2-carboxylic acid dimethylamide; 1-(5-Chloro-1H-
indole-2-carbonyl)-4-methyl-piperazine-2-carboxylic acid
dimethylamide; (5-Chloro-1H-indol-2-yl)-(3-hydroxymethyl-4-
methyl-piperazin-1-yl)-methanone; (5-Chloro-1H-indol-2-yl)-(3-
methoxymethyl-4-methyl-piperazin-1-yl)-methanone; (5-Chloro-
1H-indol-2-yl)-(2-methoxymethyl-4-methyl-piperazin-1-yl)-
methanone; (5-Chloro-1H-indol-2-yl)-(4-methyl-3-
methylaminomethyl-piperazin-1-yl)-methanone; (5-Chloro-1H-
indol-2-yl)-(4-methyl-2-methylaminomethyl-piperazin-1-yl)-
methanone; (5-Chloro-1H-indol-2-yl)-(3-dimethylaminomethyl-4-
methyl-piperazin-1-yl)-methanone; and (5-Chloro-1H-indol-2-yl)-
(2-dimethylaminomethyl-4-methyl-piperazin-1-yl)-methanone.

15

26. A pharmaceutical composition comprising a compound of claim 1
and a pharmaceutically acceptable carrier.

27. A pharmaceutical composition comprising a compound of claim 2
and a pharmaceutically acceptable carrier.

20

28. A pharmaceutical composition comprising a compound of claim 3
and a pharmaceutically acceptable carrier.

25

29. A pharmaceutical composition of claim 23, comprising a
compound selected from (5-Chloro-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (5-Fluoro-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (5-Bromo-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (5-Methyl-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (5,7-Difluoro-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (7-Chloro-1H-indol-2-yl)-(4-methyl-
piperazin-1-yl)-methanone; (5,7-Dichloro-1H-indol-2-yl)-(4-
methyl-piperazin-1-yl)-methanone; (3,5-Dichloro-1H-indol-2-yl)-(4-

30

5

methyl-piperazin-1-yl)-methanone; (6-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (1H-Indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone; (7-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-benzofuran-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (1H-Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanethione.

10 30. A packaged drug comprising (a) a pharmaceutical composition comprising a compound of claim 1, 2, or 3 and a pharmaceutically acceptable carrier, and (b) instructions for the administration of said composition for the treatment or prevention of an H₄-mediated disease or condition.

15 31. A method for treating an H₄-mediated condition in a patient, said method comprising administering to the patient a pharmaceutically effective amount of a composition comprising a compound of claim 1.

20 32. A method for treating an H₄-mediated condition in a patient, said method comprising administering to the patient a pharmaceutically effective H₄-inhibiting amount of a composition comprising a compound of claim 1.

25 33. A method of claim 32 wherein said compound is a compound of claim 2.

30 34. A method of claim 32, wherein said compound is a compound of claim 3.

35. A method of claim 32, wherein said compound is selected from: (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Fluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-

5 Methyl-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5,7-
Difluoro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (7-
Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-méthanone; (5,7-
Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (3,5-
Dichloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (6-
Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (1H-
Indol-2-yl)-(3-methyl-piperazin-1-yl)-methanone; (7-Bromo-1H-
indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone; (5-Bromo-
benzofuran-2-yl)-(4-methyl-piperazin-1-yl)-methanone; and (1H-
Indol-2-yl)-(4-methyl-piperazin-1-yl)-methanethione.

10

15 36. A method of claim 32, wherein said H₄-mediated condition is
selected from: inflammatory disorders, asthma, psoriasis,
rheumatoid arthritis, ulcerative colitis, Crohn's disease,
inflammatory bowel disease, multiple sclerosis, allergic disorders,
autoimmune disease, lymphatic disorders, and immunodeficiency
disorders.

20 37. A method of claim 36, wherein said H₄- mediated condition is an
inflammatory disorder or an allergic disorder.

25 38. A method of claim 37, wherein said inflammatory disorder is an
inflammation-mediated condition selected from: acute
inflammation, allergic inflammation, and chronic inflammation.

30 39. A method for treating asthma in a patient, said method
comprising administering to the patient a pharmaceutically
effective amount of a composition comprising a compound of
claim 1, 21, or 22.

40. A method for treating an allergic disorder in a patient, said
method comprising administering to the patient a
pharmaceutically effective amount of a composition comprising a

compound of claim 1, 21, or 22.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072548 A3

(51) International Patent Classification⁷: C07D 209/42,
A61K 31/404, A61P 43/00, C07D 401/12

(21) International Application Number: PCT/US02/07168

(22) International Filing Date: 8 March 2002 (08.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/274,900 9 March 2001 (09.03.2001) US
60/343,259 21 December 2001 (21.12.2001) US

(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL,
INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ
08869-0602 (US).

(72) Inventors: CARRUTHERS, Nicholas, I.; 14370 Silver
Heights Road, Poway, CA 92064 (US). CHAI, Wenyi; 9519 Compass Point Drive South, San Diego, CA 92126
(US). DVORAK, Curt, A.; 7657 Angelino Road, San
Diego, CA 92126 (US). EDWARDS, James, P.; 8723
Hesby Court, San Diego, CA 92129 (US). GRICE,
Cheryl, A.; 3449 Camino Corte, Carlsbad, CA 92009
(US). JABLONOWSKI, Jill, A.; 13651 Freeport Road,
San Diego, CA 92129 (US). KARLSSON, Lars; 336
Fern Glen, La Jolla, CA 92037 (US). KHATUYA, Hari-
pada; 13624 Via Cima Bella, San Diego, CA 92129
(US). KREISBERG, Jennifer, D.; 12825 Caminito del
Canto, Del Mar, CA 92014 (US). KWOK, Annette,

K.; 9975 Paseo Montril, San Diego, CA 92129 (US).
LOVENBERG, Timothy, W.; 13252 Courtland Terrace,
San Diego, CA 92130 (US). LY, Kiev, S.; 10620 Dabney
Drive, #172, San Diego, CA 92126 (US). PIO, Barbara;
3898 Ashford Street, San Diego, CA 92111 (US). SHAH,
Chandravadan, R.; 14213 Dalhousie Road, San Diego,
CA 92129 (US). SUN, Siquan; 13919 Amber Sky Lane,
San Diego, CA 92129 (US). THURMOND, Robin, L.;
4654 Constance Drive, San Diego, CA 92115 (US). WEI,
Jianmei; 12516 Senda Panacea, San Diego, CA 92129
(US). XIAO, Wei; 4043 Carmel Springs Way, San Diego,
CA 92130 (US).

(74) Agent: SHEN, Evelyn, D.; Johnson & Johnson, One Johnson
& Johnson Plaza, New Brunswick, NJ 08933 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

[Continued on next page]

(54) Title: HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS.

WO 02/072548 A3



(57) Abstract: A compound of formula (I) wherein: wherein X₄ is NR₁ or S; X₁ is CR₃; X₂ is NR_c or O, provided that X₂ is NR_c where X₁ is N; X₃ is N; to treat or prevent disorders and conditions mediated by the histamine H₄ receptor.



Published:

— *with international search report*

(88) Date of publication of the international search report:

12 December 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/07168

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D209/42 A61K31/404 A61P43/00 C07D401/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 21 57 424 A (CHEMISCHE WERKE ALBERT AG) 24 May 1973 (1973-05-24) * page 40, 41, 43 and 44: compounds nr 1-11, 14-19, 30, 32 and 41 * --- -/-	1,26

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

- *&* document member of the same patent family

Date of the actual completion of the international search

20 August 2002

Date of mailing of the international search report

03/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Van Bijlen, H

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/07168

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 78, no. 15, 16 April 1973 (1973-04-16) Columbus, Ohio, US; abstract no. 92398x, BUROV, YU. V. ET AL.: "Derivatives of benzofuran-2-carboxylic acids and their action on the central nervous system." XP002210361 abstract & KHIM.-FARM. ZH., vol. 6, no. 10, - 1972 pages 17-21, -& DATABASE CAPLUS 'Online' CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CA 78:92398, XP002210367 compounds with RN 40713-12-0, -19-7, -20-0 and -23-3 * ---	1,26
X	WO 99 05121 A (LABORATORIOS DEL DR. ESTEVE, S.A.) 4 February 1999 (1999-02-04) * page 13, example 20 * ---	1
X	CHEMICAL ABSTRACTS, vol. 130, no. 4, 25 January 1999 (1999-01-25) Columbus, Ohio, US; abstract no. 32657p, CHANG, MAYLAND ET AL.: "Absorption, distribution, metabolism, and excretion of atevirdine in the rat." XP002210362 abstract & DRUG METAB. DISPOS., vol. 26, no. 10, - 1998 pages 1008-1018, -& DATABASE CAPLUS 'Online' CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CA 130:32657, XP002210368 compound with RN 216780-63-1, -65-3, 216781-13-4 and 160360-41-8 ---	1
X	EP 0 624 575 A (ADIR ET COMPAGNIE) 17 November 1994 (1994-11-17) example 35 ---	1,26
X	WO 99 09025 A (PFIZER PRODUCTS INC.) 25 February 1999 (1999-02-25) example 18 ---	1
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/07168

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>SIAVOSH MAHBOOBI ET AL.: "Synthetic 2-aryliindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents" <i>JOURNAL OF MEDICINAL CHEMISTRY</i>, vol. 44, no. 26, - 2001 pages 4535-4553, XP002210359 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 * page 4540, scheme 2 and page 4552: compounds 73, 74 and 76 *</p> <p>---</p>	1
P, X	<p>WO 01 64676 A (SCIOS, INC.) 7 September 2001 (2001-09-07) * page 3/20: compound 130 *</p> <p>---</p>	1
X	<p>CHEMICAL ABSTRACTS, vol. 127, no. 3, 21 July 1997 (1997-07-21) Columbus, Ohio, US; abstract no. 34243n, TAKASHIMA, JUNKO: "Preparation of benzofuran derivatives as antihypertensive agents." XP002210363 abstract & JP 97 124631 A (SHENSI RESEARCH INSTITUTE OF PHARMACOLOGY; MITSUBISHI CHEMICAL CO., LTD) 13 May 1997 (1997-05-13) * compound II (RN 190775-72-5)</p> <p>---</p>	1,26
X	<p>CHEMICAL ABSTRACTS, vol. 121, no. 19, 7 November 1994 (1994-11-07) Columbus, Ohio, US; abstract no. 230739u, ZAWADOWSKI, TEODOR ET AL.: "Synthesis of piperazinamides of benzofuran-2- and -3-carboxylic acids." XP002210364 abstract & ACTA POL. PHARM., vol. 50, no. 6, - 1993 pages 457-459, -& DATABASE CAPLUS 'Online' CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CA 121:230739, XP002210369 compounds with RN 157370-23-5, -25-7, -21-3, -22-4, -26-8, -27-9 and -28-0</p> <p>---</p> <p>-/-</p>	1,26

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/07168

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M FONT ET AL.: "Indoles and pyridazino(4,5-b)indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY., vol. 30, no. 12, - 1995 pages 963-971, XP002210360 EDITIONS SCIENTIFIQUE ELSEVIER, PARIS., FR ISSN: 0223-5234 * page 965, compounds 7j, 7k and 7l * ---	1,26
X	CHEMICAL ABSTRACTS, vol. 119, no. 3, 19 July 1993 (1993-07-19) Columbus, Ohio, US; abstract no. 28161c, SHIBAYAMA, KATSUHIRO ET AL.: "Preparation of piperazine or piperidine group-containing indoles and their use as anti-inflammatory, antiallergy, and anti-PAF agents." XP002210365 abstract & JP 09 325131 A (TORAY INDUSTRIES) 16 December 1997 (1997-12-16) -& DATABASE CAPLUS 'Online' CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CA 119:28161, XP002210370 compounds with RN 148247-63-6 and -69-2 ---	1,26
X	WO 91 09849 A (THE UPJOHN COMPANY) 11 July 1991 (1991-07-11) * preparation 129; example 12 *	1,26
X	EP 0 318 235 A (TAKEDA CHEMICAL INDUSTRIES, LTD.) 31 May 1989 (1989-05-31) * working example 7 *	1,26
	---	-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/07168

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 111, no. 19, 6 November 1989 (1989-11-06) Columbus, Ohio, US; abstract no. 174134x, KOMOTO, TERUO ET AL.: "Preparation of (indolylcarbonyl)piperazines as platelet aggregation inhibitors." XP002210366 abstract & JP 89 132579 A (S.S. PHARMACEUTICAL CO., LTD.) 25 May 1989 (1989-05-25) -& DATABASE CAPLUS 'Online' CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CA 111:171134, XP002210371 compounds with RN 123215-95-2, -96-3, -97-4, -98-5, -99-6, 123216-00-2, -01-3, -02-4, -03-5, -04-6 and 123245-81-8 ----</p>	1,26
A	<p>EP 0 978 512 A (SOCIETE CIVILE BIOPROJET) 9 February 2000 (2000-02-09) claims</p> <p>----</p>	1,26
A	<p>EP 0 324 431 A (FUJISAWA PHARMACEUTICAL CO., LTD.) 19 July 1989 (1989-07-19) claims</p> <p>----</p>	1,26

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-19, 26-28, 30-34, 36-40 (partly)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty of compounds of formula (I). So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, with respect to claim 1 and its dependent claims, the search and the search report can only be considered comprehensive for the compounds of the specific examples of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/07168

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 31-40 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: 1-19, 26-28, 30-34, 36-40 (partly)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/07168

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 2157424	A 24-05-1973	DE 2240665 A1 DE 2157424 A1 AT 336625 B AT 469674 A AT 327207 B AT 469774 A AT 336626 B AT 923274 A AT 327203 B AT 981272 A BE 791501 A1 CA 1025866 A1 CH 613202 A5 CH 612430 A5 CH 592080 A5 CH 590265 A5 ES 408565 A1 FR 2160611 A1 GB 1407854 A JP 1004705 C JP 52053871 A JP 54040555 B JP 52053872 A JP 55019219 B JP 52053873 A JP 57060350 B JP 1032329 C JP 48061484 A JP 55023831 B NL 7215416 A ,B, SE 408423 B US 4374990 A US 4115569 A	07-03-1974 24-05-1973 10-05-1977 15-09-1976 26-01-1976 15-04-1975 10-05-1977 15-09-1976 26-01-1976 15-04-1975 17-05-1973 07-02-1978 14-09-1979 31-07-1979 14-10-1977 29-07-1977 01-11-1975 29-06-1973 24-09-1975 30-06-1980 30-04-1977 04-12-1979 30-04-1977 24-05-1980 30-04-1977 18-12-1982 29-01-1981 28-08-1973 25-06-1980 22-05-1973 11-06-1979 22-02-1983 19-09-1978
WO 9905121	A 04-02-1999	ES 2125206 A1 AU 744633 B2 AU 8340398 A BG 104100 A BR 9810772 A CN 1268124 T EE 200000037 A EP 1006110 A1 WO 9905121 A1 HU 0002517 A2 JP 2001510831 T LT 2000004 A ,B LV 12457 A LV 12457 B NO 20000294 A NZ 502400 A PL 338143 A1 SI 20269 A SK 722000 A3 US 6372746 B1 ZA 9806437 A	16-02-1999 28-02-2002 16-02-1999 31-05-2001 15-08-2000 27-09-2000 16-10-2000 07-06-2000 04-02-1999 28-06-2001 07-08-2001 25-07-2000 20-04-2000 20-07-2000 17-03-2000 29-06-2001 25-09-2000 31-12-2000 14-08-2000 16-04-2002 07-04-1999
EP 624575	A 17-11-1994	FR 2705095 A1 AU 6197494 A	18-11-1994 15-09-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/07168

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 624575	A	CA	2123267 A1	13-11-1994
		EP	0624575 A1	17-11-1994
		JP	7002770 A	06-01-1995
		NZ	260505 A	26-09-1995
		ZA	9403255 A	11-01-1995
WO 9909025	A 25-02-1999	AU	8457298 A	08-03-1999
		BG	104069 A	31-05-2001
		BR	9811557 A	22-08-2000
		CN	1265660 T	06-09-2000
		EP	1003739 A2	31-05-2000
		HR	980441 A1	30-04-1999
		HU	0003425 A2	28-10-2001
		WO	9909025 A2	25-02-1999
		NO	20000722 A	14-02-2000
		PL	338947 A1	04-12-2000
		SK	1352000 A3	14-08-2000
		TR	200000414 T2	21-08-2000
		ZA	9807304 A	14-02-2000
WO 0164676	A 07-09-2001	AU	4192701 A	12-09-2001
		WO	0164676 A2	07-09-2001
JP 97124631	A	NONE		
JP 9325131	A 16-12-1997	NONE		
WO 9109849	A 11-07-1991	AT	142621 T	15-09-1996
		AU	654808 B2	24-11-1994
		AU	7173291 A	24-07-1991
		CA	2071529 A1	29-06-1991
		DE	69028552 D1	17-10-1996
		DE	69028552 T2	06-03-1997
		DK	507861 T3	03-03-1997
		EP	0507861 A1	14-10-1992
		ES	2093090 T3	16-12-1996
		GR	3021655 T3	28-02-1997
		HK	1002235 A1	07-08-1998
		HU	61296 A2	28-12-1992
		HU	211241 B3	28-11-1995
		JP	7110852 B	29-11-1995
		KR	179637 B1	20-03-1999
		LV	10264 A , B	20-10-1994
		MX	9203454 A1	01-08-1992
		RU	2099335 C1	20-12-1997
		WO	9109849 A1	11-07-1991
		US	5563142 A	08-10-1996
		US	5489593 A	06-02-1996
EP 318235	A 31-05-1989	EP	0318235 A2	31-05-1989
		JP	1230570 A	14-09-1989
		US	4937246 A	26-06-1990
JP 89132579	A	NONE		
EP 978512	A 09-02-2000	EP	0978512 A1	09-02-2000
		AU	5511999 A	21-02-2000
		CA	2321881 A1	10-02-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/07168

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 978512	A	WO	0006254 A2	10-02-2000
		EP	0982300 A2	01-03-2000
		EP	1100503 A2	23-05-2001
EP 324431	A 19-07-1989	AT	74131 T	15-04-1992
		AU	2837089 A	20-07-1989
		CA	1336605 A1	08-08-1995
		CN	1035112 A ,B	30-08-1989
		DE	68901039 D1	30-04-1992
		DK	733788 A	15-07-1989
		EP	0324431 A1	19-07-1989
		ES	2032339 T3	01-02-1993
		FI	890123 A ,B,	15-07-1989
		GR	3004987 T3	28-04-1993
		HU	49871 A2	28-11-1989
		HU	9500342 A3	28-09-1995
		IE	63476 B	19-04-1995
		IL	88903 A	15-03-1993
		JP	1221377 A	04-09-1989
		JP	2028613 C	19-03-1996
		JP	7059577 B	28-06-1995
		KR	130899 B1	23-04-1998
		NO	890155 A ,B,	17-07-1989
		SU	1804460 A3	23-03-1993
		SU	1814645 A3	07-05-1993
		RU	2039056 C1	09-07-1995
		US	4935432 A	19-06-1990
		US	5017703 A	21-05-1991
		ZA	8900099 A	25-10-1989
		PH	27110 A	16-03-1993

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)